Document:

Exhibit 10.08

 

 

 

 

EXECUTIVE EMPLOYMENT AGREEMENT

 

THIS
AGREEMENT is made effective as of the 1st day of February, 2017.

 

BETWEEN:

 

ZOMEDICA PHARMACEUTICALS INC.,
a body corporate duly incorporated pursuant to the laws of the State of Delaware and having an office in the City of Ann Arbor,
Michigan (hereinafter referred to as the "Corporation")

 

- and -

 

Robert
Dimarzo, an individual residing in Chappaqua, New York, USA (hereinafter referred to
as the "Executive")

 

ARTICLE
1

INTERPRETATION

 

		1.1	The
                                         phrase "this Agreement" shall include all terms and provisions of this agreement
                                         in writing between the parties hereto, including the recitals. 

 

		1.2	Wherever
                                         in this Agreement the masculine, feminine or neuter gender is used, it shall be construed
                                         as including all genders, as the context so requires; and wherever the singular number
                                         is used, it shall be deemed to include the plural and vice versa, where the context
                                         so requires. 

 

		1.3	Time
                                         shall in all respects be of the essence of this Agreement. 

 

		1.4	The
                                         division of this Agreement into Articles, Sections and subsections or any other divisions
                                         and the inclusion of headings are for convenience only and shall not affect the construction
                                         or interpretation of all or any part hereof. 

 

		1.5	Each
                                         party's rights may be exercised concurrently or separately and the exercise of any one
                                         remedy shall not be deemed an exclusive election of such remedy or preclude the exercise
                                         of any other remedy. 

 

ARTICLE
2

TERM OF AGREEMENT

 

		2.1	The
                                         term of this Agreement (the "Term") will begin on the date first written above
                                         (the "Effective Date") and continue for one (1) year, unless terminated prior
                                         to then in accordance with this Agreement. This Agreement shall automatically be extended
                                         from year to year, in one (1) year terms, unless either party elects not to extend this
                                         Agreement by providing written notice of such non-extension to the other party at least
                                         ninety (90) days prior to the end of any current Term.

 

     

    	 	- 2 -	 

    

ARTICLE
3

EMPLOYMENT OF THE EXECUTIVE

 

		3.1	The
                                         Corporation wishes to employ at the Effective Date the Executive as EVP ("Executive
                                         Vice President) and the Executive wishes to be employed at the Effective Date by the
                                         Corporation on the terms and conditions set forth herein. 

 

		3.2	The
                                         Executive shall report directly to the Corporation's Chief Executive Officer (the "CEO").

 

ARTICLE
4

PERFORMANCE OF DUTIES

 

		4.1	The
                                         Executive agrees to devote his business time, attention, skill and efforts to the faithful
                                         performance and discharge of his duties and responsibilities as Executive Vice President
                                         of the Corporation in conformity with professional standards, in a prudent and workmanlike
                                         manner and in a manner consistent with the obligations imposed under applicable law.
                                         The Executive shall promote the interests of the Corporation and each other corporation
                                         or other organization which is controlled directly or indirectly by the Corporation and/or
                                         the Parent (as hereinafter defined) (each an "Affiliate" and collectively the
                                         "Affiliates") in carrying out the Executive's duties and responsibilities and
                                         shall not deliberately and knowingly take any action, or fail to take any action which
                                         failure could, or reasonably be expected to, have a material and adverse effect on the
                                         business of the Corporation or any of its Affiliates.

 

		4.2	The
                                         Executive and the Corporation agree that the Executive's principal place of business
                                         initially will be in New York and, further, that any reassignment of his principal place
                                         of business will be to a place in Europe mutually agreed upon by the Executive and the
                                         CEO. The Executive understands that his duties and responsibilities will require him
                                         to travel on a regular basis to Europe as well as to other locations in the world from
                                         time to time to further the business and interests of the Corporation.

 

		4.3	The
                                         Executive discloses, represents and affirms that he has no obligation toward any person
                                         or entity, including former employers, that would be incompatible with this Agreement
                                         or that could create an impediment to or conflict of interest with the performance of
                                         his duties with the Corporation and its affiliates.

 

		4.4	The
                                         Executive shall be appointed as Executive Vice President of the Corporation's parent
                                         company, Zomedica Pharmaceuticals Corp. (the "Parent"), an Alberta incorporated
                                         public company whose common shares are listed and posted for trading on the TSX Venture
                                         Exchange. The Executive shall receive no compensation for his services under this Section
                                         4.4 in addition to his compensation otherwise payable under this Agreement.

 

		4.5	The
                                         Corporation and the Executive agree that the Executive may continue to sit upon the board
                                         of directors of any corporations or organizations on which he serves on the Effective
                                         Date as long as the CEO and the Executive mutually agree that his membership on any such
                                         board of directors does not unreasonably interfere with the performance of Executive's
                                         duties and responsibilities under this Agreement and, solely with the prior written authorization
                                         of the CEO, the Executive may serve on any other board of directors.

 

ARTICLE
5

COMPENSATION

 

		5.1	Annual
                                         Base Salary. The Corporation shall pay the Executive a base annual salary (the "Base
                                         Salary") which initially shall be TWO HUNDRED AND FIFTEEN THOUSAND DOLLARS US (US$215,000),
                                         subject to applicable taxable withholding and deductions and payable in accordance with
                                         the Corporation's standard payroll practice for executive officers. The Base Salary shall
                                         be reviewed annually by the Board or a committee of the Board and may be increased in
                                         accordance with the Corporation's compensation policy.

 

     

    	 	- 3 -	 

    

		5.2	Quarterly
                                         Cash Bonus. The Executive shall be eligible to earn a quarterly cash bonus (the "Quarterly
                                         Bonus"). Such Quarterly Bonus will be calculated upon the achievement of performance
                                         objectives that will be established by the Board (as recommended by the Corporation's
                                         Compensation Committee) within thirty (30) days prior to the beginning of a fiscal year.
                                         The granting of a Quarterly Bonus is also based on the business performance of the Corporation
                                         and subject to approval by the Board. The Quarterly Bonus, if any, payable for any calendar
                                         year shall be paid no later than 30 days following each Quarter. Finally, if the Executive's
                                         employment terminates (other than for Cause) on or after July 1 of a calendar year, he
                                         shall be entitled to the payment of a pro rata part of any Quarterly Bonus, which would
                                         have been payable if he had continued to be employed by the Corporation through the end
                                         of such calendar year.

 

		5.3	Monthly
                                         Allowance. The Corporation shall provide the Executive a monthly allowance in the
                                         amount of FOUR THOUSAND DOLLARS US (US$4,000), which shall be paid as an allowance in
                                         respect of the following items: (i) vehicle; (ii) insurance (medical, dental, vision)
                                         premiums; and (iii) tax preparation. The foregoing amount shall be allocated among the
                                         foregoing items in such manner as the Executive determines, subject to the approval of
                                         the CEO (acting reasonably).

 

		5.4	Business
                                         Expenses. The Corporation shall reimburse the Executive, upon presentation of valid
                                         receipts or vouchers, for reasonable entertainment, travel, telephone and other business
                                         expenses (including but not limited to expenses incurred in connection with computer
                                         repair/maintenance and office materials), incurred on behalf of or at the request of
                                         the Corporation or an Affiliate and which are in accordance with the Corporation's policies
                                         and rules; provided, however: (a) the amount of such expenses eligible for reimbursement
                                         in any calendar year shall not affect the expenses eligible for reimbursement in another
                                         calendar year; (b) no right to such reimbursement may be exchanged or liquidated
                                         for another benefit or payment; and (c) any reimbursements of such expenses shall
                                         be made as soon as practicable under the circumstances, but in any event no later than
                                         the end of the calendar year following the calendar year in which the related expenses
                                         are incurred by the Executive.

 

		5.5	Flight
                                         Expenditures. For greater certainty, it is acknowledged and agreed that, in the event
                                         that the Executive is required to travel by air to/from the United States to/from any
                                         of the following destinations in connection with the completion of his duties hereunder:
                                         (a) Europe; (b) South America; and (c) Asia Pacific; the Executive shall be entitled
                                         to fly "Business Class" (or an equivalent thereto). For any required travel
                                         within the United States, or to/from the United States to Canada and/or to Central America,
                                         the Executive shall (in the event that air travel is the most reasonable travel alternative)
                                         be entitled to fly "Economy Class" (or an equivalent thereto).

 

		5.6	OTHER
                                         BENEFITS. Subject to eligibility requirements and participation rules, the Executive
                                         may participate in all of the employee benefit plans maintained by the Corporation and
                                         its Affiliates that are available to employees whose principal place of business is the
                                         same as the Executive's principal place of business.

 

ARTICLE
6

VACATION

 

		6.1	The
                                         Executive shall be entitled to a paid annual vacation of three (3) weeks in accordance
                                         with the Corporation's vacation policy for executives. The Executive agrees that exercise
                                         of the vacation benefit shall be prearranged in consultation with the CEO. The full annual
                                         vacation benefit shall be extended to the Executive for 2017.

 

     

    	 	- 4 -	 

    

		6.2	In
                                         addition to the foregoing, the Executive shall be entitled to up to five (5) business
                                         days' vacation during the period between December 25 and December 31 of each year, which
                                         days shall not count towards the three (3) week allotment set forth in Section 6.1.

 

ARTICLE
7

STOCK OPTIONS

 

		7.1	Initial
                                         Grant: Following the execution of this Agreement, the Executive shall be granted
                                         500,000 options to acquire common shares in the capital of the Parent, with the price
                                         and terms of such options to be established by the Board of Directors of the Parent in
                                         accordance with the Parent's stock option plan. 

 

		7.2	Stock
                                         Options. In addition to the Base Salary, Quarterly Bonuses, benefits and other compensation
                                         contemplated hereunder, the Executive shall also be eligible to receive future grants
                                         of stock options from the Parent, from time to time, to the extent determined by the
                                         Board of Directors of the Parent at its sole discretion, which options shall vest in
                                         accordance with a schedule to be determined by the Board of Directors of the Parent at
                                         its sole discretion, and which shall have an exercise price equal to the market price
                                         of the Parent's common shares on the date of grant, or such higher price as may be required
                                         by any stock exchange on which the shares of the Parent are listed, or if the Parent
                                         is not publicly traded, at such a price as shall be determined by the Board of Directors
                                         of the Parent in its sole discretion. In addition to the initial grant of options contemplated
                                         in Section 7.1 above, it is further acknowledged and agreed that the Executive shall
                                         be entitled to the following additional grants of options to acquire common shares in
                                         the capital of the Parent: (i) 250,000 options upon the six (6) month anniversary of
                                         the Effective Date, subject to completion of six (6) month performance objectives, as
                                         established by the CEO; and (ii) 250,000 options upon the twelve (12) month anniversary
                                         of the Effective Date, subject to completion of twelve (12) month performance objectives,
                                         as established by the CEO. The foregoing future grants of stock options are contingent
                                         upon this Agreement being in full force and effect at the scheduled time of such option
                                         grants (with no material breaches of this Agreement having occurred). The terms of such
                                         future stock option grants shall be determined by the Board of Directors of the Parent
                                         at the time of grant and in accordance with the Parent's stock option plan and applicable
                                         TSX Venture Exchange rules and policies. Any options granted to the Executive by the
                                         Board of Directors of the Corporation, or pursuant to the terms of this Agreement, may
                                         be exercised only in accordance with the terms and conditions of the Stock Option Agreement
                                         that is entered into in connection therewith.

 

		7.3	Accelerated
                                         Vesting. Subject to regulatory approval, the Corporation covenants and agrees that
                                         any Stock Option Agreements between the Parent and the Executive shall provide that all
                                         stock options held by the Executive, whether vested or unvested, shall immediately vest
                                         and be exercisable by the Executive:

 

     

    	 	- 5 -	 

    

		(a)	upon
                                         a termination by the Corporation without Cause as more specifically provided for in Article
                                         8.2; or

 

		(b)	the
                                         resignation by the Executive for Good Reason, as more specifically provided for in Article
                                         8.3.

 

		7.3	Rules
                                         of the Stock Exchanges. The Corporation and the Executive expressly acknowledge and
                                         agree that all options to purchase shares of the Parent to which the Executive shall
                                         be entitled hereunder, and any changes to such options (including, without limitation,
                                         changes provided for in this Agreement), shall be subject to the approval and the regulations,
                                         policies and by-laws of each of the stock exchanges on which the common voting shares
                                         of the Parent are then listed. The Corporation covenants to use its reasonable commercial
                                         efforts to obtain any such approvals and to ensure that all options are in compliance
                                         with such regulations, policies and by-laws.

 

ARTICLE
8

TERMINATION

 

		8.1	At-Will
                                         Employment. Nothing in this Agreement shall be construed to alter the at-will employment
                                         relationship between the Corporation and the Executive. Subject to the terms set forth
                                         in this Agreement, either the Corporation or the Executive may terminate the Executive's
                                         employment at any time for any reason, with or without Cause, as defined in Section 8.2
                                         below.

 

		8.2	Termination
                                         for Cause. The Executive's employment may be terminated by the Corporation upon simple
                                         notice in writing transmitted to the Executive, without the Corporation (or any of its
                                         Affiliates) being bound to pay any compensation whatsoever if termination is for any
                                         of the following reasons, each of which constitutes cause (hereinafter, "Cause"):

 

		(a)	The
                                         Executive is declared bankrupt or insolvent or is placed under protective supervision,
                                         which situations the Executive acknowledges to be incompatible with the continuation
                                         of his employment.

 

		(b)	The
                                         Executive becomes physically or mentally disabled to such an extent as to make him unable
                                         to perform the essential functions of his duties normally and adequately for an aggregate
                                         of six (6) months during a period of twelve (12) consecutive months. In such a case,
                                         the Executive may continue to benefit under short-term and long-term disability insurance
                                         plans, subject to the terms of such plans, if any. The Corporation's ability to terminate
                                         the Executive as a result of any disability shall be to the extent permitted by applicable
                                         state or federal law.

 

		(c)	The
                                         Executive breaches the terms of this Agreement.

 

		(d)	The
                                         Executive fundamentally or materially fails to perform his duties as Executive Vice President
                                         of the Corporation.

 

		(e)	There
                                         is a conclusive determination that the Executive has committed any fraud, theft, embezzlement
                                         or other criminal act of a similar nature.

 

		(f)	The
                                         Executive has committed serious misconduct or willful or gross negligence in the performance
                                         of his duties.

 

		(g)	The
                                         Executive fails or refuses to follow reasonable directives of the CEO.

 

		(h)	The
                                         Executive engages in willful or reckless conduct, causing material damage to the Corporation
                                         or the Parent (or their Affiliates) or the Corporation's or the Parent's (or their Affiliates')
                                         business.

 

		(i)	The
                                         Executive misuses or abuses alcohol, drugs or controlled substances.

 

		(j)	The
                                         Executive uses or discloses in an unauthorized way the Corporation's or the Parent's
                                         (or any of their Affiliates') confidential or trade secret information.

 

     

    	 	- 6 -	 

    

		(k)	The
                                         Executive conducts himself publicly, by speech or behavior, in such a manner as to cause
                                         public embarrassment, scandal or ridicule to the Corporation or the Parent, any of their
                                         Affiliates or any of their employees.

 

Provided,
however, no reason set forth in this Section 8.2 shall constitute Cause unless (1) the Executive upon notice is given a reasonable
period to effect a cure or a correction; (2) the reason is curable or correctible as determined by the Board; and, (3)
the reason clearly and adversely affects the Executive's ability to continue to perform his duties and responsibilities under
this Agreement.

 

		8.3	Good
                                         Reason. The Executive shall have the right to resign at any time for any of the following
                                         reasons, each of which shall constitute Good Reason:

 

		(a)	Any
                                         change in the Executive's direct reporting relationship.

 

		(b)	Any
                                         reduction (absent the Executive's express, written consent) in the Executive's duties
                                         and responsibilities as Executive Vice President of the Corporation.

 

Provided,
however, no reason set forth in this Section 8.3 shall constitute Good Reason unless the Corporation upon express, written notice
is given a reasonable period to effect a cure or a correction.

 

		8.4	Termination
                                         by Death. In the event of the Executive's death during his period of employment,
                                         the Corporation's obligation to make payments under this Agreement shall terminate on
                                         the date of death, except the Corporation shall pay the Executive's estate or surviving
                                         designated beneficiary or beneficiaries, as appropriate, any earned but unpaid salary
                                         and bonus and reimburse business expenses incurred but not reimbursed as of his date
                                         of death. Vesting of any stock options outstanding on the date of death shall be exercisable
                                         only to the extent the Executive's right to exercise was vested on his date of death.

 

		8.5	Voluntary
                                         Termination. In the event Executive wishes to resign for any reason other than Good
                                         Reason or the Corporation wishes to terminate his employment without Cause, the Executive
                                         shall give, or receive, as applicable at least thirty (30) days prior written notice
                                         of such resignation or termination, whichever is applicable. Any such notice shall not
                                         relieve either the Executive or the Corporation of their mutual obligations to perform
                                         under this Agreement or to relieve the Corporation to compensate the Executive during
                                         such notice period for any earned but unpaid salary and bonus and reimburse business
                                         expenses incurred but not reimbursed as of his date of termination.

 

		8.6	Termination
                                         Without Cause Or Resignation For Good Reason. In the event that the Executive has
                                         a "separation from service" within the meaning of a §409A of the US Internal
                                         Revenue Code of 1986, as amended (a "Separation from Service") as a result
                                         of the Corporation terminating the Executive's employment without Cause at a date that
                                         is at least twelve (12) months following the Effective Date or the Executive resigning
                                         for Good Reason at a date that is at least twelve (12) months following the Effective
                                         Date, (1) Executive's right to exercise all then outstanding stock options granted to
                                         him shall fully and immediately vest on the effective date of his Separation from Service;
                                         (2) the Corporation shall pay to Executive in a lump sum (less applicable tax withholdings)
                                         an amount equal to: (i) twelve (12) months Base Salary
                                         (paid  in  accordance  with  the 
                                         Corporation's usual payroll procedures); and
                                         (ii) any Quarterly Bonus allocable or payable
                                         prior to the date of termination.

 

     

    	 	- 7 -	 

    

ARTICLE
9

CONFIDENTIALITY

 

		9.1	The
                                         Executive acknowledges that he has received and will receive or conceive, in carrying
                                         on or in the course of his work during his employment with the Corporation, confidential
                                         information pertaining to the activities, the technologies, the operations and the business,
                                         past, present and future, of the Corporation or its affiliates or related or associated
                                         companies, which information is not in the public domain. The Executive acknowledges
                                         that such confidential information belongs to the Corporation and/or its affiliates and
                                         that its disclosure or unauthorized use could be damaging or prejudicial to the Corporation
                                         and/or its affiliates and contrary to their best interests.

 

		9.2	Accordingly,
                                         the Executive agrees to respect the confidentiality of such information and not to make
                                         use of or disclose it to, or to discuss it with, any person, other than in the ordinary
                                         course of his duties with the Corporation and its Affiliates, or as required under applicable
                                         law, without the explicit prior written authorization of the Corporation.

 

		9.3	This
                                         undertaking to respect the confidentiality of such information and not to make use of
                                         or disclose or discuss it to or with any person shall survive and continue to have full
                                         effect notwithstanding the termination of the Executive's employment with the Corporation,
                                         so long as such confidential information does not become public as a result of an act
                                         by the Corporation or a third party, which act does not involve the fault of one of its
                                         executives.

 

		9.4	The
                                         term confidential information includes, among other things:

 

		(a)	products,
                                         formulae, processes and composition of products, as well as raw materials and ingredients,
                                         of whatever kind, that are used in their manufacture;

 

		(b)	technical
                                         knowledge and methods, quality control processes, inspection methods, laboratory and
                                         testing methods, information processing programs and systems, manufacturing processes,
                                         plans, drawings, tests, test reports and software;

 

		(c)	equipment,
                                         machinery, devices, tools, instruments and accessories;

 

		(d)	financial
                                         information, production cost data, marketing strategies, raw materials supplies, suppliers,
                                         staff and client lists and related information, marketing plans, sales techniques and
                                         policies, including pricing policies, sales and distribution data and present and future
                                         expansion plans; and

 

		(e)	research,
                                         experiments, inventions, discoveries, developments, improvements, ideas, industrial secrets
                                         and know-how.

 

		9.5	The
                                         Executive agrees to keep confidential and not disclose to any third party both the existence
                                         and the terms of this Agreement, except if disclosure is required by regulation or law.
                                         In the event that the Executive is required to disclose the existence or terms of this
                                         Agreement pursuant to subpoena or other duly issued court order, Executive shall give
                                         prompt notice to the Corporation of such subpoena or court order to allow the Corporation
                                         sufficient opportunity to contest such subpoena or court order.

 

ARTICLE
10

NON-SOLICITATION OF OFFERS

 

		10.1	The
                                         Executive shall not compete with the Corporation nor with any of its Affiliates, directly
                                         or indirectly. He shall not participate in any capacity whatsoever in a business that
                                         would directly or indirectly compete with the Corporation or with any of its Affiliates,
                                         including, without limitation, as an executive, director, officer, employer, principal,
                                         agent, fiduciary, administrator of another's property, associate, independent contractor,
                                         franchisor, franchisee, distributor or consultant unless such participation is fully
                                         disclosed to the Board and approved in writing in advance. In addition, the Executive
                                         shall not have any interest whatsoever in such an enterprise, including, without limitation,
                                         as owner, shareholder, partner, limited partner, lender or silent partner. This noncompetition
                                         covenant is limited as follows:

 

     

    	 	- 8 -	 

    

		(a)	As
                                         to the time period, to the duration of the Executive's employment and for a period
                                         of one (1) year following the date of termination of his employment;

 

		(b)	As
                                         to the geographical area, the territory in which a specific product had been actively
                                         exploited by the Corporation and/or its Affiliates during the twelve (12) months preceding
                                         the employment termination date;

 

		(c)	As
                                         to the nature of the activities, to duties or activities which are identical or substantially
                                         similar to those performed or carried on by the Executive at or during the twelve (12)
                                         months preceding the employment termination date.

 

		10.2	The
                                         foregoing stipulation shall nevertheless not prevent the Executive from buying or holding
                                         shares or other securities of a corporation or entity other than the Corporation whose
                                         securities are publicly traded on a recognized stock exchange where the securities so
                                         held by the Executive do not represent more than five percent (5%) of the voting shares
                                         of such other corporation or entity and do not allow for its control.

 

		10.3	The
                                         Executive also undertakes, for the same period and in respect of the same territory referred
                                         to hereinabove in subsections 10.1(a), (b) and (c), not to solicit clients or do anything
                                         whatsoever to induce or to lead any person to end, in whole or in part, business relations
                                         with the Corporation or any of its affiliates.

 

		10.4	The
                                         Executive also undertakes, for the same period and in respect of the same territory referred
                                         to hereinabove in subsections 10.1(a), (b) and (c), not to induce, attempt to induce
                                         or otherwise interfere in the relations which the Corporation or which any of its affiliates
                                         has with their distributors, suppliers, representatives, agents and other parties with
                                         whom the Corporation or any of its affiliates deals.

 

		10.5	The
                                         Executive also undertakes, for the same period and in respect of the same territory referred
                                         to in subsections 10.1(a), (b) and (c), not to induce, attempt to induce or otherwise
                                         solicit the personnel of the Corporation to leave their employment with the Corporation
                                         or any of its Affiliates nor to hire the personnel of the Corporation or any of its Affiliates
                                         for any enterprise in which the Executive has an interest.

 

		10.6	The
                                         Executive acknowledges that the provisions of this Section 10 are limited as to the time
                                         period, the geographic area and the nature of the activities to what the parties deem
                                         necessary to protect the legitimate interests of the Corporation and its Affiliates,
                                         while allowing the Executive to earn his living.

 

		10.7	Nothing
                                         in this Section 10 shall operate to reduce or extinguish the obligations of the Executive
                                         arising at law or under this contract which survive at the termination of this Agreement
                                         in reason of their nature and, in particular, without limiting the foregoing, the Executive's
                                         duty of loyalty and obligation to act faithfully, honestly and ethically.

 

     

    	 	- 9 -	 

    

ARTICLE
11

OWNERSHIP OF INTELLECTUAL PROPERTY

 

		11.1	The
                                         Executive hereby assigns and agrees to assign to the Corporation all of his intellectual
                                         property rights as of their creation and to make full and prompt disclosure to the Corporation
                                         of all information relating to anything made or designed by him or that may be made or
                                         designed by him during the period of his employment, whether alone or jointly with other
                                         persons, or within a period of two (2) years following the termination of his employment
                                         and resulting from or arising out of any work performed by the Executive on behalf of
                                         the Corporation (or its affiliates) or connected with any matter relating or possibly
                                         relating to any business in which the Corporation or any of its affiliates or related
                                         or associated companies is involved unless specifically released from such obligation
                                         in writing by the Corporation's Board of Directors.

 

		11.2	In
                                         addition, the Executive renounces all moral rights in any document or work realized during
                                         the period of his employment related to his employment by the Corporation. The Executive
                                         acknowledges that the Corporation has the right to use, modify or reproduce any such
                                         document or work realized by the Executive, at its entire discretion, without the Executive's
                                         authorization and without his name being mentioned.

 

		11.3	At
                                         any time during the period of his employment or after the termination of his employment,
                                         the Executive shall sign, acknowledge and deliver, at the Corporation's expense, but
                                         without compensation other than a reasonable sum for his time devoted thereto if his
                                         employment has then terminated, any document required by the Corporation to give effect
                                         to Section 11.1, including patent applications and documents evidencing the assignment
                                         of ownership. The Executive shall also provide such other assistance as the Corporation
                                         or one of its affiliates may require with respect to any proceeding or litigation relating
                                         to the protection or defense of intellectual property rights belonging to the Corporation
                                         or any of its affiliates. The entirety of this Section 11 shall be binding on the Executive's
                                         assignees and legal representatives.

 

ARTICLE
12

OWNERSHIP OF FILES AND OTHER PROPERTY

 

		12.1	Any
                                         property of the Corporation, including any file, sketch, drawing, letter, report, memorandum
                                         or other document, any equipment, machinery, tool, instrument or other device, any diskette,
                                         recording tape, compact disc, software, electronic communication device or any other
                                         property, which comes into the Executive's control or possession during his employment
                                         with the Corporation in the performance or in the course of his duties, regardless of
                                         whether he has participated in its preparation or design, how it may have come under
                                         his control or into his possession and whether it is an original or a copy, shall at
                                         all times remain the property of the Corporation and, upon the termination of the Executive's
                                         employment, shall promptly be returned to the Corporation or its designated representative..
                                         The Executive may not keep a copy or give one to a third party without the prior expressly
                                         written permission of the Corporation.

 

ARTICLE
13

ENTIRE AGREEMENT AND TERMINATION OF PRIOR CONTRACTS

 

		13.1	This
                                         Agreement contains the entire understanding of the parties with respect to the matters
                                         contained or referred to herein. There are no promises, covenants or undertakings by
                                         either party hereto to the other, other than those expressly set forth herein. This Agreement
                                         supersedes and replaces any earlier agreement, whether oral or in writing or partly oral
                                         and partly in writing, between the parties hereto, or between any party hereto and the
                                         corporate representative of any other party hereto, respecting the provision of services
                                         by the Executive to the Corporation. 

 

     

    	 	- 10 -	 

    

ARTICLE
14

AMENDMENT OF THE AGREEMENT

 

		14.1	To
                                         be valid and enforceable, any amendment to this Agreement must be confirmed in writing
                                         by each of the Corporation and the Executive.

 

ARTICLE
15

NOTICES

 

		15.1	Any
                                         notice given hereunder shall be given in writing and sent by registered or certified
                                         mail or hand-delivered. If such notice is sent by registered or certified mail, it shall
                                         be deemed to have been received five (5) business days following the date of its mailing
                                         if the postal services are working normally. If such is not the case, the notice must
                                         be hand-delivered or served by bailiff, at the discretion of the sender. In the case of
                                         hand-delivery or service, the notice shall be deemed to have been received the same day.
                                         It is agreed that if the delivery date is a non business day, the notice shall be deemed
                                         to have been received on the following business day.

 

		15.2	For
                                         purposes of mailed or hand-delivered notices to be effectively delivered under this provision,
                                         the notices must be addressed as follows:

 

		(a)	For
                                         the Corporation: 1250, 639 – 5th Avenue S.W., Calgary, Alberta T2P 0M9.
                                         

 

		(b)	For
                                         the Executive: 18 Turner Drive, Chappaqua, New York 10514.

 

ARTICLE
16

INDEMNITY AND INSURANCE

 

		16.1	The
                                         Corporation covenants, both during and after the Executive's term of service, to indemnify
                                         and hold harmless the Executive and his legal representatives, to the maximum extent
                                         permitted by Delaware law (provided that the Executive acted honestly and in good faith
                                         with a view to the best interests of the Corporation and, in the case of a criminal or
                                         administrative action or proceeding that is enforced by monetary penalty, the Executive
                                         had reasonable grounds for believing that his conduct was lawful), from and against:

 

		(a)	all
                                         costs, charges, liabilities and expenses whatsoever that the Executive may sustain or
                                         incur in or about or in relation to any action, suit or proceeding that is brought, commenced
                                         or prosecuted against the Executive for or in respect of any act, deed, matter or thing
                                         whatever made, done or permitted or not made, done or permitted by the Executive in or
                                         about the execution of his duties as a director or officer of the Corporation or its
                                         subsidiaries; and

 

		(b)	all
                                         other costs, charges, liabilities and expenses that the Executive may sustain or incur
                                         (including, without limitation, all income tax, sales tax and excise tax liabilities
                                         resulting from any payment made pursuant to this indemnity) in or about or in relation
                                         to the affairs of the Corporation or its subsidiaries or his position as a director or
                                         officer of the Corporation or its subsidiaries.

 

		16.2	The
                                         Corporation further agrees that any costs, charges and expenses referred to in paragraph 16.1(a)
                                         above shall be paid in advance of the final disposition of any such action or proceeding
                                         upon receipt by the Corporation of a written undertaking by the Executive to repay such
                                         amount if it shall ultimately be determined that the Executive is not entitled to be
                                         indemnified in accordance with the terms and conditions of this Indemnity and Delaware
                                         law.

 

     

    	 	- 11 -	 

    

		16.3	The
                                         Corporation further agrees, both during and after the Executive's term of service, to
                                         use its reasonable best efforts to obtain any approval or approvals necessary for such
                                         indemnification and to co-operate with the Executive and to provide the Executive with
                                         access to any evidence which the Corporation may have or control, which would enable
                                         the Executive to make application or obtain any approval or approvals necessary for such
                                         indemnification.

 

ARTICLE
17

SUCCESSORS

 

		17.1	This
                                         Agreement shall be binding on the successors, assignees and legal representatives of
                                         all of the parties hereto.

 

ARTICLE
18

JURISDICTION

 

		18.1	This
                                         Agreement shall be governed by and interpreted in accordance with the laws, including
                                         conflicts of laws, by the State of Delaware in the United States of America. Each of
                                         the parties hereby irrevocably attorns to the jurisdiction of the Courts of the State
                                         of Delaware with respect to any matters arising out of this Agreement. 

 

ARTICLE
19

SEVERABILITY

 

		19.1	If
                                         any provision of this Agreement or the application thereof is held invalid, the invalidity
                                         shall not affect other provisions or applications of this Agreement, which can be given
                                         effect without the invalid provisions or applications and, to this end, the provisions
                                         of this Agreement are declared to be severable.

 

ARTICLE
20

MEDIATION

 

		20.1	The
                                         Corporation and the Executive hereby expressly agree that with respect to any dispute
                                         arising under this Agreement, such dispute shall be resolved through binding mediation.
                                         Any such mediation shall: (1) take place at a location mutually agreed upon by the Corporation
                                         and the Executive; and (2) be conducted by a recognized panel of three professional
                                         mediators or which can be comprised of three experienced business experts from the pharmaceutical
                                         or biotechnical industry mutually agreed upon by the Corporation and the Executive. With
                                         respect to any such mediation panel, one mediator shall be selected by the Corporation,
                                         one mediator shall be selected by the Executive, and one mediator shall be selected by
                                         mutual agreement between the Corporation and the Executive. Each of the parties hereto
                                         shall bear their own, respective costs of such mediation.

 

ARTICLE
21

LANGUAGE

 

		21.1	All
                                         of the parties hereto expressly agree that this Agreement be drafted, read and interpreted
                                         in the English language.

 

ARTICLE
22

GENERAL

 

		22.1	This
                                         Agreement and the obligations of the Executive hereunder shall not be assigned by either
                                         party hereto, in whole or in part, without the prior consent of the other party hereto,
                                         which consent may be withheld for any reason.

 

     

    	 	- 12 -	 

    

		22.2	Each
                                         party shall do and perform all such acts and things and execute and deliver all such
                                         instruments and documents and writings and give all such further assurances as may be
                                         necessary to give full effect to the provisions and intent of this Agreement.

 

		22.3	The
                                         Executive agrees that after termination of employment hereunder for any reason whatsoever,
                                         he will tender his resignation from any position he may hold as an officer or director
                                         of the Corporation, the Parent or their Affiliates.

 

		22.4	This
                                         Agreement shall enure to the benefit of and be binding upon the Executive and his executors
                                         and administrators and upon the Corporation and its successors and assigns.

 

		22.5	Neither
                                         party can waive or shall be deemed to have waived any right it has under this Agreement
                                         (including any waiver under this section) except to the extent that such waiver is in
                                         writing.

 

		22.6	The
                                         Corporation agrees to co-operate with the Executive, to the extent permitted by applicable
                                         tax laws, so as to permit the Executive to consider payments hereunder on termination
                                         of employment to be retirement benefits.

 

ARTICLE
23

COUNTERPARTS

 

		23.1	This
                                         Agreement may be executed in counterparts, each of which shall be deemed one and the
                                         same Agreement.

 

[Reminder of page
intentionally left blank.]

 

 

     

    	 	- 13 -	 

    

IN WITNESS WHEREOF
the parties have executed this Agreement as of the date and year first above written.

 

 

	 	 	ZOMEDICA PHARMACEUTICALS CORP.
	 	 	 	 
	 	 	 	 
	 	 	Per:	/s/ Gerald Solensky Jr.
	 	 	 	Gerald Solensky Jr.
	 	 	 	Chairman, CEO
		 	 	 
		 	 	 
	/s/ David Stowell	 	/s/ Robert DiMarzo
	Witness	 	Robert Dimarzo
	Name: David Stowell	 	 	 

 

 

 

 

 

    

     

    

ADDENDUM
RE EMPLOYMENT AGREEMENT

 

THIS ADDENDUM is dated effective
as of February 1, 2017,

 

BETWEEN:

 

ZOMEDICA PHARMACEUTICALS INC.,
a body corporate duly incorporated pursuant to the laws of the State of Delaware and having an office in the City of Ann Arbor,
Michigan (hereinafter referred to as the "Corporation")

 

- and -

 

Robert
Dimarzo, an individual residing in Chappaqua, New York, USA (hereinafter referred to as the "Executive")

 

WHEREAS the parties hereto entered
into an employment agreement dated effective February 1, 2017 (the "Employment Agreement")

 

AND WHEREAS the parties hereto wish
to set forth certain additional terms to supplement the Employment Agreement, as set out in this Addendum;

 

NOW THEREFORE, in consideration
of the premises and the respective covenants and agreements set forth herein and in the Employment Agreement, the parties hereto
agree as follows:

 

		1.	Interpretation

 

This Addendum is supplemental to and shall
form one agreement with the Employment Agreement, and the Employment Agreement and this Addendum shall be read together and have
effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument.

 

		2.	Amendment

 

The parties hereto acknowledge
and agree that a Quarterly Cash Bonus, as contemplated in Section 5.2 of the Employment Agreement shall be payable to the Executive
and that in respect of the 2017 fiscal year, the following amounts shall be payable, subject to completion of the corresponding
performance criteria on or before the applicable Bonus Payment Date.

 

	Quarterly Bonus Amount	 	Bonus Performance Criterion	 	Bonus
    Payment Date
	U.S.$9,000	 	Conference Participation	 	March 31, 2017
	 	 	 	 	 
	U.S.$9,000	 	Globalization of Products 	 	June 30, 2017
	 	 	And International Strategic Plan	 	
	 	 	 	 	 
	U.S.$9,000	 	Launch of 2 Diagnostics Outside	 	September, 2017
	 	 	of USA	 	
	 	 	 	 	 
	U.S.$9,000	 	Business Development Acquisition	 	December 31, 2017
	 	 	EU	 	

 

 

Determination as to whether
the Bonus Performance Criterion have been satisfied shall be made by the Chief Executive Officer of the Corporation, in his sole
discretion (acting reasonably).

 

     

    	2

    

		3.	Confirmation

 

The parties hereto hereby acknowledge and
confirm that, except as specifically amended by the provisions of this Addendum, all of the terms and conditions contained in the
Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.

 

		4.	Enurement

 

This Addendum shall be
binding upon and shall enure to the benefit of the parties hereto and their respective heirs, successors and assigns.

 

		5.	Time

 

Time shall be of the
essence of this Agreement.

 

		6.	Governing Laws

 

This Addendum shall be
governed by and construed in accordance with the laws of the State of Delaware in the United States of America. Each of the parties
hereby irrevocably attorns to the jurisdiction of the Courts of the State of Delaware with respect to any matters arising out of
this Addendum.

 

		7.	Execution in Counterpart

 

This Addendum may be executed by the parties
in separate counterparts (and by facsimile transmission or by a scanned copy by electronic mail) each of which when so executed
and transmitted or delivered shall be an original, but all such counterparts shall together constitute one and the same agreement.

 

IN WITNESS WHEREOF the parties hereto
have caused this Addendum to be duly executed as of the date and year first above written.

 

	 	 	ZOMEDICA PHARMACEUTICALS CORP.
	 	 	 	 
	 	 	 	 
	 	 	Per:	/s/ Gerald Solensky Jr.
	 	 	 	Gerald Solensky Jr.
	 	 	 	Chairman, CEO
		 	 	 
		 	 	 
	/s/ David Stowell	 	/s/ Robert DiMarzo
	Witness	 	Robert Dimarzo
	Name: David StowellExhibit 10.13

 

 

 

SUBSCRIPTION FOR COMMON SHARES

 

TO:Zomedica Pharmaceuticals Corp. (the "Corporation")

 

The undersigned (the "Subscriber") hereby irrevocably
subscribes for and agrees to purchase the number of common shares ("Common Shares") of the Corporation set forth
below for the aggregate subscription price ("Aggregate Subscription Amount") set forth below, representing a subscription
price of C$1.50 per Common Share, upon and subject to the terms and conditions set forth in "Terms and Conditions of Subscription
for Common Shares of Zomedica Pharmaceuticals Corp." attached hereto (together with this page and attached Schedules, the
"Subscription Agreement"). In addition to this face page, the Subscriber must also complete all applicable
schedules attached hereto.

 

	
         

        ______________________________________________

        Full Legal Name of Subscriber (please print)

         

        By: ___________________________________________

               Signature of
Subscriber or its Authorized Representative

        ______________________________________________

        Official Title or Capacity (please print)

        ______________________________________________

        Name of Signatory (please print name of individual
whose signature appears above if different than name of Subscriber)

         

        ______________________________________________

        Subscriber's Address (including postal code)

         

        ______________________________________________

         

        ______________________________________________

        Telephone Number (including area code)

         

        ______________________________________________

        e-mail Address

         

        By executing this Subscription Agreement, you are
consenting to the collection, use and disclosure of personal information in the manner described in the privacy notices on pages
14 and 15 of this Subscription Agreement.

         
	
         

         

         

         
	
         

        Aggregate Subscription Amount: $ __________________

	 	 
	
         

         

         

         
	
         

        Number of Common Shares: _______________________

	 	 
	 	
        Disclosed Beneficial Purchaser Information:

         

        If the Subscriber is signing as agent for a principal and is not
        deemed to be purchasing as principal pursuant to applicable securities legislation, complete the following and ensure that the
        Schedules and Exhibits, as applicable, are completed in respect of such principal:

         

        _____________________________________________

        (Name of Principal)

         

        

        _____________________________________________

        (Principal's Address)

         

        _____________________________________________

         

         

        _____________________________________________

        (Telephone Number)                             (E-mail Address)

         

	 	 	 
	
         

        Register the Common Shares (if different from address
given above) as follows:

         

        _____________________________________________

        Name

         

        _____________________________________________

        Account reference, if applicable

         

        _____________________________________________

        Address (including postal code)

         

        _____________________________________________

         

         

        _____________________________________________

         

         
	
         

         

         

         
	
         

        Deliver the Common Shares (if different from address given
        above) as follows:

         

        _____________________________________________

        Name

         

        _____________________________________________

        Account reference, if applicable

         

        _____________________________________________

        Contact Name

         

        _____________________________________________

        Address (including postal code)

         

        _____________________________________________

        Telephone Number (including area code)

         

	 

 

ACCEPTANCE: The Corporation hereby accepts the
subscription as set forth above on the terms and conditions contained in this Subscription Agreement.

 

	ZOMEDICA PHARMACEUTICALS CORP.	 	 	 	_______________,2016

 

	Per:	 	 	No.:

This is the first page of an agreement
comprised of 15 pages (excluding the Schedules and Exhibits hereto).

 

    	 

    	Zomedica Pharmaceuticals Corp.
Subscription Agreement for Common Shares
	 	Page 2 of 14

    

PLEASE MAKE SURE THAT YOUR SUBSCRIPTION INCLUDES:

 

		1.	a signed copy of this Subscription Agreement;

 

		2.	a certified cheque or bank draft in an amount equal to the Aggregate Subscription Amount payable
to "Zomedica Pharmaceuticals Corp." OR

 

a wire transfer to:

 

Incoming Canadian $ wires:

 

Beneficiary Bank:

Bank Address: 

Transit/Branch #:

Account #:

Bank #:

SWIFT Code:

Currency:

Beneficiary:

 

 

Incoming US $ wires:

 

Intermediary/Correspondent Bank:

SWIFT Code:

ABA #:

Beneficiary Bank:

Bank Address: 

Transit #:

Account #:

Bank #:

SWIFT Code:

Currency:

Beneficiary:

 

PLEASE NOTE THAT THE FAILURE TO PROVIDE
ALL OF THE ABOVE INFORMATION IN RESPECT OF WIRE TRANSFERS MAY RESULT IN THE COMPLETION OF YOUR SUBSCRIPTION FOR SECURITIES
HEREUNDER BEING REJECTED OR DELAYED.

 

		3.	if the Subscriber is purchasing Common Shares as an "accredited investor", one (1) copy
of the Representation Letter in the form attached to this Subscription Agreement as Schedule "A" (including a duly completed
and initialed copy of Exhibit A to Schedule "A") and, if you are an individual described in paragraphs (j), (k),
or (l) of the definition of "accredited investor" in Section 1.1 of NI 45-106 (which definition is reproduced in Exhibit
A to Schedule "A"), a duly completed and signed copy of Exhibit B to Schedule "A";

 

		4.	if the Subscriber is purchasing as a "family member, close personal friend or close personal
business associate" and:

 

		o	resident in, or subject to the laws of, any province of Canada except Saskatchewan or Ontario,
one (1) copy of a Representation Letter in the form attached to this Subscription Agreement as Schedule "B";

 

		o	resident in, or subject to the laws of, the Province of Saskatchewan, one (1) copy of a
Representation Letter in the form attached to this Subscription Agreement as Schedule "B" and one (1) copy of a Risk
Acknowledgement Form in the form attached to this Subscription Agreement as Schedule "C" [Note: If applicable,
the Subscriber must sign 2 copies of Schedule "C" and the Subscriber and the Corporation must each receive a signed copy];
and

 

		o	resident in, or subject to the laws of, the Province of Ontario, one (1) duly completed
copy of the Risk Acknowledgement Form in the form attached to this Subscription Agreement as Schedule "D" and executed
by the Subscriber and by the applicable family member, close personal friend or close personal business associate and has retained
one signed copy of such Risk Acknowledgement Form for the Subscriber's records;

 

		5.	if the Subscriber is a resident of a jurisdiction outside of both Canada and the United States,
a copy of the Representation Letter in the form attached to this Subscription Agreement as Schedule "E";

 

		6.	if the Subscriber is a U.S. Purchaser, a copy of the Certification of U.S. Purchaser in the form
attached to this Subscription Agreement as Schedule "F";

 

		7.	all Subscribers must provide a properly completed and duly executed copy of the Private Placement
Questionnaire in the form attached as Schedule "G" to this Subscription Agreement; and

 

    	 

    	Zomedica Pharmaceuticals Corp.
Subscription Agreement for Common Shares
	 	Page 3 of 14

    

		8.	if the Subscriber is not an individual, one manually signed and duly completed Corporate Placee
Registration Form in the form required by the TSX Venture Exchange and as attached as Schedule "H" to this Subscription
Agreement, provided that such form is not required if the Subscriber has previously filed a Corporate Placee Registration Form
with the TSX Venture Exchange and the information contained in such form has not changed since the last filing.

 

PLEASE
DELIVER THE AFOREMENTIONED DOCUMENTS TO:

 

Tingle Merrett LLP 

1250, 639 – 5th Avenue S.W. 

Calgary, Alberta T2P 0M9 

 

Attention: Paul Bolger 

T: 403-571-8006 

F: 403-571-8008 

E: pbolger@tinglemerrett.com

 

 

 

 

 

 

 

 

 

    	 

    	Zomedica Pharmaceuticals Corp.
Subscription Agreement for Common Shares
	 	Page 4 of 14

    

TERMS AND CONDITIONS OF SUBSCRIPTION FOR

COMMON SHARES OF ZOMEDICA PHARMACEUTICALS CORP.

 

 

 

		1.	Definitions. In this Subscription Agreement:

 

		(a)	"Aggregate Subscription Amount" has the meaning set forth on the face page hereof;

 

		(b)	"Closing Date" means such date(s) as the Corporation may determine;

 

		(c)	"Common Shares" means common shares in the capital of the Corporation;

 

		(d)	"Corporation" means Zomedica Pharmaceuticals Corp., a corporation organized under the
laws of Alberta;

 

		(e)	"Offering" shall have the meaning ascribed thereto in paragraph 2(b) hereof; and

 

		(f)	"U.S. Purchaser" is (a) any person that receives or received an offer of the securities
while in the United States or (b) any person that is in the United States at the time the purchaser's buy order was originated
or this Subscription Agreement was executed or delivered.

 

		2.	Acknowledgements of the Subscriber. The Subscriber acknowledges (on its own behalf
and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting) that:

 

		(a)	this subscription is subject to rejection or acceptance by the Corporation in whole or in part,
and is effective only upon acceptance by the Corporation;

 

		(b)	the Common Shares subscribed for by the Subscriber hereunder form part of a larger issue and sale
by the Corporation of Common Shares at a subscription price of C$1.50 per Common Share (the "Offering");

 

		(c)	the Offering is not subject to any minimum amount and that the Subscriber's subscription may be
the only subscription;

 

		(d)	the Subscriber is responsible for obtaining such legal advice as it considers appropriate in
connection with the execution, delivery and performance by it of this Subscription Agreement; 

 

		(e)	there is no government or other insurance scheme covering the Common Shares; and

 

		(f)	there are risks associated with an investment in the Common Shares and, as a result, the Subscriber
may lose its entire investment.

 

		3.	Representations, Warranties and Covenants of the Subscriber. By executing this Subscription
Agreement, the Subscriber (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting)
represents, warrants and covenants to the Corporation and its counsel (and acknowledges that the Corporation and its counsel are
relying thereon) that:

 

		(a)	if the Subscriber is an individual, the Subscriber is of the full age of majority in the jurisdiction
in which this Subscription Agreement is executed and is legally competent to execute and deliver this Subscription Agreement, to
perform all of its obligations hereunder, and to undertake all actions required of the Subscriber hereunder;

 

		(b)	if the Subscriber is not an individual, the Subscriber has the requisite power, authority, legal
capacity and competence to execute and deliver and be bound by this Subscription Agreement, to perform all of its obligations hereunder,
and to undertake all actions required of the Subscriber hereunder, and all necessary approvals of its directors, partners, shareholders,
trustees or otherwise with respect to such matters have been given or obtained;

 

		(c)	if the Subscriber is a body corporate, partnership, unincorporated association or other entity,
the Subscriber has been duly incorporated or created and is validly subsisting under the laws of its jurisdiction of incorporation
or creation;

 

		(d)	this Subscription Agreement has been duly and validly authorized, executed and delivered by, and
constitutes a legal, valid, binding and enforceable obligation of, the Subscriber;

 

		(e)	the execution, delivery and performance by the Subscriber of this Subscription Agreement and the
completion of the transactions contemplated hereby do not and will not result in a violation of any law, regulation, order or ruling
applicable to the Subscriber, and do not and will not constitute a breach of or default under any of the Subscriber's constating
documents (if the Subscriber is not an individual) or any agreement or covenant to which the Subscriber is a party or by which
it is bound;

 

    	 

    	Zomedica Pharmaceuticals Corp.
Subscription Agreement for Common Shares
	 	Page 5 of 14

    

		(f)	the Subscriber confirms that the Subscriber (and, if the Subscriber is not purchasing as principal,
each beneficial purchaser for whom the Subscriber is acting):

 

		(i)	has such knowledge in financial and business affairs as to be capable of evaluating the merits
and risks of its investment in the Common Shares;

 

		(ii)	is capable of assessing the proposed investment in the Common Shares as a result of the Subscriber's
own experience or as a result of advice received from a person registered under applicable securities legislation;

 

		(iii)	is aware of the characteristics of the Common Shares and the risks relating to an investment therein;
and

 

		(iv)	is able to bear the economic risk of loss of its entire investment in the Common Shares;

 

		(g)	the Subscriber understands that no securities commission, stock exchange, governmental agency,
regulatory body or similar authority has made any finding or determination or expressed any opinion with respect to the merits
of investing in the Common Shares;

 

		(h)	the Subscriber understands and acknowledges that no prospectus or registration statement has been
filed by the Corporation with any securities commission or similar regulatory authority in any jurisdiction in connection with
the issuance of the Common Shares and that the Common Shares are being offered for sale only on a "private placement"
basis and that the sale of the Common Shares is conditional upon such sale being exempt from the requirements to file and obtain
a receipt for a prospectus or file a registration statement, and the requirement to sell securities through a registered dealer,
or upon the issuance of such orders, consents or approvals as may be required to enable such sale to be made without complying
with such requirements, and that as a consequence of acquiring the Common Shares pursuant to such exemptions:

 

		(i)	the Subscriber is restricted from using some of the civil remedies otherwise available under applicable
securities laws in Canada;

 

		(ii)	the Subscriber will not receive information that would otherwise be required to be provided to
it under applicable securities laws in Canada; and

 

		(iii)	the Corporation is relieved from certain obligations that would otherwise apply under applicable
securities laws in Canada;

 

		(i)	the Subscriber confirms that neither the Corporation nor any of its directors, employees, officers,
agents, representatives or affiliates have made any representations (written or oral) to the Subscriber:

 

		(i)	regarding the future value of the Common Shares;

 

		(ii)	that any person will resell or repurchase the Common Shares; or

 

		(iii)	that any person will refund the purchase price of the Common Shares;

 

		(j)	the Subscriber confirms that it has been advised to consult its own legal and financial advisors
with respect to the suitability of the Common Shares as an investment for the Subscriber, the tax consequences of purchasing and
dealing with the Common Shares, and the resale restrictions and "hold periods" to which the Common Shares are or may
be subject under applicable securities legislation or stock exchange rules, and has not relied upon any statements made by or purporting
to have been made on behalf of the Corporation with respect to such suitability, tax consequences, resale restrictions and "hold
periods";

 

		(k)	except for the Subscriber's knowledge regarding its subscription for Common Shares hereunder, the
Subscriber has no knowledge of a "material fact" or a "material change" (as those terms are defined in the
Securities Act (Alberta)) in the affairs of the Corporation that has not been generally disclosed;

 

		(l)	the Subscriber is resident in the jurisdiction indicated on the face page of this Subscription
Agreement as the "Subscriber's Address" and the purchase by and sale to the Subscriber of the Common Shares, and any
act, solicitation, conduct or negotiation directly or indirectly in furtherance of such purchase and sale (whether with or with
respect to the Subscriber or any beneficial purchaser) has occurred only in such jurisdiction;

 

    	 

    	Zomedica Pharmaceuticals Corp.
Subscription Agreement for Common Shares
	 	Page 6 of 14

    

		(m)	the Subscriber acknowledges that it and/or the Corporation may be required to provide applicable
securities regulatory authorities or stock exchanges with information concerning the identities of the beneficial purchasers of
the Common Shares and the Subscriber agrees that, notwithstanding that the Subscriber may be purchasing the Common Shares as agent
for an undisclosed principal, the Subscriber will provide to the Corporation, on request, particulars as to the identity of such
undisclosed principal as may be required by the Corporation in order to comply with the foregoing;

 

		(n)	unless the Subscriber satisfies subsection 3(o), the Subscriber satisfies one of subsections (i),
(ii), (iii) or (iv) below:

 

		(i)	if the Subscriber is resident in or otherwise subject to the applicable securities laws of any
province of Canada, the Subscriber is purchasing the Common Shares as principal (or is deemed to be purchasing as principal)
for its own account, not for the benefit of any other person, the Subscriber is an "accredited investor" as defined in
National Instrument 45-106 entitled Prospectus Exemptions ("NI 45-106") (or, if applicable for Subscribers
in Ontario, the corresponding categories for the definition of an "accredited investor" as defined in Section 73.3 of
the Securities Act (Ontario)), which definitions are reproduced in Exhibit A to Schedule "A" attached hereto,
the Subscriber was not created or used solely to purchase or hold securities as an accredited investor as described in paragraph
(m) of the definition of "accredited investor" in NI 45-106 and reproduced in Exhibit A to Schedule "A" hereto,
the Subscriber is not a trust company or trust corporation registered under the laws of Prince Edward Island that is not registered
or authorized under the Trust and Loan Companies Act (Canada) or under comparable legislation in another jurisdiction of
Canada and the Subscriber has executed and delivered to the Corporation a Representation Letter in the form attached hereto
as Schedule "A" indicating that the Subscriber fits within one of the categories of "accredited investor" set
forth in such definitions (including a duly completed and initialed copy of Exhibit A to Schedule "A") and, if the Subscriber
is an individual described in paragraphs (j), (k), or (l) of the definition of "accredited investor" in Section 1.1 of
NI 45-106, a duly completed and signed copy of Exhibit B to Schedule "A";OR

 

		(ii)	if the Subscriber is resident in or otherwise subject to the applicable securities laws of any
province of Canada except Ontario and is not an "accredited investor" as defined in NI 45-106, it is purchasing
the Common Shares as principal for its own account and not for the benefit of any other person, and the Subscriber is a "family
member, close personal friend or close personal business associate" of the Corporation or an affiliate of the Corporation,
as defined in NI 45-106 (which definition is reproduced in the Exhibit to Schedule "B" attached hereto) and the Subscriber
has executed and delivered to the Corporation a Representation Letter in the form attached hereto as Schedule "B" (and,
if resident in Saskatchewan, has executed and delivered to the Corporation a Risk Acknowledgement Form in the form attached
as Schedule "C" hereto and has retained one signed copy for the Subscriber's records) and no commission or finder's
fee will be paid to any director, officer, founder or control person of the Corporation or an affiliate, and to the best of the
Subscriber's knowledge, no director, officer, founder or control person of the Corporation or an affiliate is entitled to a finder's
fee or commission, in each case in connection with the purchase of Common Shares pursuant to this section 3(n)(ii); OR

 

		(iii)	if the Subscriber is resident in or otherwise subject to the applicable securities laws of Ontario
and is not an "accredited investor" as defined in NI 45-106, it is purchasing the Common Shares as principal for
its own account and not for the benefit of any other person, and the Subscriber is a "family member, close personal friend
or close personal business associate" of the Corporation or an affiliate of the Corporation, as defined in NI 45-106 (which
definition is reproduced in the Exhibit to Schedule "B" attached hereto) and the Subscriber has delivered to the Corporation
a Risk Acknowledgement Form in the form attached as Schedule "D" hereto duly signed by the Subscriber AND by the applicable
family member, close personal friend or close personal business associate (as directed in the Risk Acknowledgement Form in
the form attached as Schedule "D" hereto) and has retained one signed copy for the Subscriber's records and no commission
or finder's fee will be paid to any director, officer, founder or control person of the Corporation or an affiliate, and to the
best of the Subscriber's knowledge, no director, officer, founder or control person of the Corporation or an affiliate is entitled
to a finder's fee or commission, in each case in connection with the Offering pursuant to this section 3(n)(iii); OR

 

    	 

    	Zomedica Pharmaceuticals Corp.
Subscription Agreement for Common Shares
	 	Page 7 of 14

    

		(iv)	if the Subscriber is not purchasing the Common Shares as principal or pursuant to section 3(n)(i),
3(n)(ii) or 3(n)(iii), it is duly authorized to enter into this Subscription Agreement and to execute and deliver all documentation
in connection with the purchase on behalf of each beneficial purchaser, each of whom is purchasing as principal for its own account,
not for the benefit of any other person, and not with a view to the resale or distribution of all or any of the Common Shares,
it acknowledges that the Corporation may be required by law to disclose to certain regulatory authorities the identity of each
beneficial purchaser of Common Shares for whom it may be acting, and it and each beneficial purchaser is resident in the jurisdiction
set out as the "Subscriber's Residential Address" and the purchase by and sale of the Common Shares, and any act, solicitation,
conduct or negotiation directly or indirectly in furtherance of such purchase and sale (whether with or with respect to the Subscriber
or any beneficial purchaser) has occurred only in such jurisdiction, and:

 

		(A)	it is acting as agent for a beneficial purchaser, who is disclosed on the face page of this Subscription
Agreement, who is resident in the jurisdiction set out in the "Disclosed Beneficial Purchaser Information" and who complies
with section 3(n)(i) hereof as if all references therein were to the beneficial purchaser rather than to the Subscriber and the
Subscriber has concurrently executed and delivered to the Corporation a Representation Letter in the form attached hereto as
Schedule "A" indicating that the Subscriber fits within the category of "accredited investor" set forth in
such definitions (including a duly completed and initialed copy of Exhibit A to Schedule "A") and, if the Subscriber
is an individual described in paragraphs (j), (k), or (l) of the definition of "accredited investor" in Section 1.1 of
NI 45-106, a duly completed and signed copy of Exhibit B to Schedule "A"; or

 

		(B)	it is deemed to be purchasing as principal under NI 45-106 because it is an "accredited investor"
as such term is defined in paragraphs (p) or (q) of the definition of "accredited investor" in NI 45-106 and reproduced
in Exhibit A to Schedule "A" of this Subscription Agreement (provided, however, that it is not a trust company or trust
corporation registered under the laws of Prince Edward Island that is not registered or authorized under the Trust and Loan
Companies Act (Canada) or under comparable legislation in another jurisdiction of Canada) and has concurrently executed
and delivered a Representation Letter in the form attached hereto as Schedule "A" and has initialed in the Exhibit thereto
indicating that the Subscriber satisfies one of the categories of "accredited investor" set out in paragraphs (p) or
(q) of the definition of "accredited investor" in NI 45-106 and reproduced in Exhibit A to Schedule "A" hereto;

 

		(o)	if it is not purchasing the Common Shares pursuant to section 3(n), it and each person
on whose behalf the Subscriber is contracting is a resident of a jurisdiction outside of both Canada and the United States, it
has concurrently executed and delivered the Representation Letter in the form attached to this Subscription Agreement as Schedule
"E" and will provide such evidence of compliance with all matters described in such Representation Letter as the
Corporation or its counsel may request including that: (a) the purchase of the Common Shares does not contravene any of the applicable
securities laws in the Subscriber's jurisdiction of residence and does not trigger (i) any obligation to prepare and file a prospectus,
an offering memorandum or similar document, or any other ongoing reporting requirements with respect to such purchase or otherwise,
or (ii) any registration or other obligation on the part of the Corporation; and (b) the sale of the Common Shares as contemplated
in this Subscription Agreement would, if completed, be made pursuant to an exemption from the prospectus and registration requirements
under applicable securities legislation of the Subscriber's jurisdiction of residence;

 

    	 

    	Zomedica Pharmaceuticals Corp.
Subscription Agreement for Common Shares
	 	Page 8 of 14

    

		(p)	if it is a "U.S. Purchaser", it and each person on whose behalf the Subscriber is
contracting is a resident in the United States, it has concurrently executed and delivered the "Certification of U.S. Purchaser"
in the form attached hereto as Schedule "F" and will provide such evidence of compliance with all matters described
in such Certification of U.S. Purchaser as the Corporation or its counsel may request including that: (a) the purchase of the Common
Shares does not contravene any of the applicable securities laws in the Subscriber's jurisdiction of residence and does not trigger
(i) any obligation to prepare and file a prospectus, an offering memorandum or similar document, or any other ongoing reporting
requirements with respect to such purchase or otherwise, or (ii) any registration or other obligation on the part of the Corporation;
and (b) the sale of the Common Shares as contemplated in this Subscription Agreement would, if completed, be made pursuant to an
exemption from the prospectus and registration requirements under applicable securities legislation of the Subscriber's jurisdiction
of residence;

 

		(q)	the Subscriber understands that it may not be able to resell the Common Shares except in accordance
with limited exemptions available under applicable securities legislation, regulatory policy and stock exchange rules, and that
the Subscriber is solely responsible for (and the Corporation is not in any way responsible for) the Subscriber's compliance with
applicable resale restrictions;

 

		(r)	the Subscriber acknowledges that:

 

		(i)	no securities commission or similar regulatory authority has reviewed or passed on the merits of
the Common Shares;

 

		(ii)	there is no government or other insurance covering the Common Shares;

 

		(iii)	there are risks associated with the purchase of the Common Shares;

 

		(iv)	there are restrictions on the Subscriber's ability to resell the Common Shares and it is the responsibility
of the Subscriber to find out what those restrictions are and to comply with them before selling the Common Shares; and

 

		(v)	the Corporation has advised the Subscriber that the Corporation is relying on an exemption from
the requirements to provide the Subscriber with a prospectus and to sell securities through a person or company registered to sell
securities under the Securities Act (Alberta) and other applicable securities laws and, as a consequence of acquiring Common
Shares pursuant to this exemption, certain protections, rights and remedies provided by the Securities Act (Alberta) and
other applicable securities laws, including statutory rights of rescission or damages, will not be available to the Subscriber;

 

		(s)	the Subscriber understands that, in addition to any further legend which may be required by the
TSX Venture Exchange, any certificates representing the Common Shares are to bear a legend substantially in the following form
indicating that the resale of such securities is restricted:

 

"Unless permitted under securities
legislation, the holder of this security must not trade the security before [insert the date that is 4 months and a day after
the Closing Date]"

 

and the Subscriber further acknowledges
that it has been advised to consult its own legal counsel in its jurisdiction of residence for full particulars of the resale restrictions
applicable to it;

 

		(t)	the Subscriber has not received or been provided with, nor has it requested, nor does it have any
need to receive, any offering memorandum, or any other document (other than the annual financial statements, interim financial
statements or any other document (excluding offering memoranda, prospectuses or other offering documents) the content of which
is prescribed by statute or regulation) describing the business and affairs of the Corporation, which has been prepared for delivery
to and review by prospective purchasers in order to assist them in making an investment decision in respect of the purchase of
Common Shares pursuant to the Offering;

 

    	 

    	Zomedica Pharmaceuticals Corp.
Subscription Agreement for Common Shares
	 	Page 9 of 14

    

		(u)	the Subscriber has not become aware of any advertisement in printed media of general and regular
paid circulation or on radio, television or other form of telecommunication or any other form of advertisement (including electronic
display or the Internet) or sales literature with respect to the distribution of the Common Shares;

 

		(v)	the Subscriber is aware that the Common Shares have not been and will not be registered under the
United States Securities Act of 1933, as amended (the "U.S. Securities Act") or the securities laws of any state
and that the Common Shares may not be offered or sold, directly or indirectly, in the United States without registration under
the U.S. Securities Act or applicable state securities laws or compliance with requirements of an exemption from registration and
it acknowledges that the Corporation has no present intention of filing a registration statement under the U.S. Securities Act
or applicable state securities laws in respect of the Common Shares;

 

		(w)	unless the Subscriber is completing the Certification of U.S. Purchaser in the form attached to
this Subscription Agreement as Schedule "F" hereto, the Subscriber did not receive an offer of the Common Shares while
in the United States and was not in the United States at the time the Subscriber's buy order was originated or this Subscription
Agreement was executed or delivered;

 

		(x)	the Subscriber undertakes and agrees that it will not offer or sell any of the Common Shares in
the United States unless such securities are registered under the U.S. Securities Act and the securities laws of all applicable
states of the United States, or an exemption from such registration requirements is available;

 

		(y)	if required by applicable securities legislation, regulations, rules, policies or orders or by
any securities commission, stock exchange or other regulatory authority, the Subscriber will execute, deliver, file and otherwise
assist the Corporation in filing, such reports, undertakings and other documents with respect to the issue of the Common Shares;

 

		(z)	except as disclosed in writing to the Corporation, the Subscriber does not act jointly or in concert
with any other person or company for the purposes of acquiring securities of the Corporation;

 

		(aa)	except for this Subscription Agreement, the Subscriber has relied solely upon publicly available
information relating to the Corporation and not upon any verbal or written representation as to fact or otherwise made by or on
behalf of the Corporation, and acknowledges that the Corporation's counsel is acting as counsel to the Corporation and not as counsel
to the Subscriber;

 

		(bb)	the Subscriber has reviewed the "Privacy Notice" attached to this Subscription Agreement,
and agrees to and accepts all covenants, representations and consents as set out therein;

 

		(cc)	the funds representing the Aggregate Subscription Amount which will be advanced by the Subscriber
to the Corporation hereunder will not represent proceeds of crime for the purposes of the Proceeds of Crime (Money Laundering)
and Terrorist Financing Act (Canada) (the "PCMLTFA") and the Subscriber acknowledges that the Corporation
may in the future be required by law to disclose the Subscriber's name and other information relating to this Subscription Agreement
and the Subscriber's subscription hereunder, on a confidential basis, pursuant to the PCMLTFA. To the best of its knowledge: (i)
none of the subscription funds to be provided by the Subscriber: (A) have been or will be derived from or related to any activity
that is deemed criminal under the law of Canada, the United States of America, or any other jurisdiction; or (B) are being tendered
on behalf of a person or entity who has not been identified to the Subscriber; and (ii) it shall promptly notify the Corporation
if the Subscriber discovers that any of such representations ceases to be true, and to provide the Corporation with appropriate
information in connection therewith;

 

		(dd)	the Subscriber acknowledges that the Corporation may complete additional financings in the future
in order to develop the business of the Corporation and to fund ongoing development. There is no assurance that such financing
will be available and if available, on reasonable terms. Any such financings may have a dilutive effect on current shareholders,
including the Subscriber;

 

		(ee)	if the Subscriber is contracting under this Subscription Agreement on behalf of another person
or persons, the representations, warranties, covenants, acknowledgements, confirmations and statements made by the Subscriber in
this Subscription Agreement are true and correct with respect to such person or persons on whose behalf the Subscriber is so contracting,
as if such representations, warranties, covenants, acknowledgements, confirmations and statements were made directly by such person
or persons; and

 

    	 

    	Zomedica Pharmaceuticals Corp.
Subscription Agreement for Common Shares
	 	Page 10 of 14

    

		(ff)	the Subscriber acknowledges that an investment in the Common Shares is subject to a number of
risk factors and the Subscriber covenants and agrees to comply with applicable securities legislation, orders or policies concerning
the purchase, holding of, and resale of the Common Shares.

 

		4.	Timeliness of Representations, etc. The Subscriber agrees (on its own behalf and,
if applicable, on behalf of each person on whose behalf the Subscriber is contracting) that the representations, warranties and
covenants of the Subscriber herein will be true and correct both as of the execution of this Subscription Agreement and as of the
Closing Time (as defined herein), and will survive the completion of the distribution of the Common Shares and any subsequent disposition
by the Subscriber of any of the Common Shares.

 

		5.	Indemnity. The Subscriber acknowledges that the Corporation and its counsel are relying
upon the representations, warranties and covenants of the Subscriber set forth herein in determining the eligibility (from a securities
law perspective) of the Subscriber (or, if applicable, the eligibility of another on whose behalf the Subscriber is contracting
hereunder to subscribe for Common Shares) to purchase Common Shares under the Offering, and hereby agrees to indemnify the Corporation
and its directors, officers, employees, advisers, affiliates, shareholders and agents (including their respective legal counsel)
against all losses, claims, costs, expenses, damages or liabilities that they may suffer or incur as a result of or in connection
with their reliance on such representations, warranties and covenants. The Subscriber undertakes to immediately notify the Corporation's
counsel at Tingle Merrett LLP, 1250, 639 – 5th Avenue S.W., Calgary, Alberta T2P 0M9, Attention: Paul Bolger (fax:
(403) 571-8008), of any change in any statement or other information relating to the Subscriber set forth herein that occurs prior
to the Closing Time.

 

		6.	Deliveries by Subscriber prior to Closing. The Subscriber agrees to deliver to the
Corporation, or as the Corporation may direct, not later than 5:00 p.m. (Calgary time) on such date of which the Subscriber receives
notice:

 

		(a)	this duly completed and executed Subscription Agreement;

 

		(b)	a cheque or bank draft made payable to "Zomedica Pharmaceuticals Corp." or to "Tingle
Merrett LLP, in trust" in an amount equal to the Aggregate Subscription Amount, or payment of the same amount in such other
manner as is acceptable to the Corporation;

 

		(c)	a properly completed and duly executed copy of the appropriate investor qualification form(s) as
described on pages 2 and 3 of this Subscription Agreement;

 

		(d)	one manually signed and duly completed Private Placement Questionnaire in the form attached as
Schedule "G";

 

		(e)	if the Subscriber is not an individual, one manually signed and duly completed Corporate Placee
Registration Form in the form required by the TSX Venture Exchange and as attached as Schedule "H", provided that such
form is not required if the Subscriber has previously filed a Corporate Placee Registration Form with the TSX Venture Exchange
and the information contained in such form has not changed since the last filing; and

 

		(f)	such other documents as may be requested by the Corporation as contemplated by this Subscription
Agreement.

 

		7.	Partial Acceptance or Rejection of Subscription. The Corporation may, in its absolute
discretion, accept or reject the Subscriber's subscription for Common Shares as set forth in this Subscription Agreement, in whole
or in part, and the Corporation reserves the right to allot to the Subscriber less than the amount of Common Shares subscribed
for under this Subscription Agreement. Notwithstanding the foregoing, the Subscriber acknowledges and agrees that the acceptance
of this Subscription Agreement will be conditional upon among other things, the sale of the Common Shares to the Subscriber being
exempt from any prospectus and offering memorandum requirements of applicable securities laws. The Corporation will be deemed to
have accepted this Subscription Agreement upon the delivery at Closing of the certificates representing the Common Shares to the
Subscriber or upon the direction of the Subscriber in accordance with the provisions hereof. If this Subscription Agreement is
rejected in whole, any certified cheque(s) or bank draft(s) delivered by the Subscriber to the Corporation on account of the Aggregate
Subscription Amount for the Common Shares subscribed for will be promptly returned to the Subscriber without interest. If this
Subscription Agreement is accepted only in part, a cheque representing the amount by which the payment delivered by the Subscriber
to the Corporation (or its counsel) exceeds the subscription price of the number of Common Shares sold to the Subscriber pursuant
to a partial acceptance of this Subscription Agreement will be promptly delivered to the Subscriber without interest.

 

    	 

    	Zomedica Pharmaceuticals Corp.
Subscription Agreement for Common Shares
	 	Page 11 of 14

    

		8.	Time and Place of Closing. The sale of the Common Shares will be completed at the
offices of Tingle Merrett LLP, counsel to the Corporation, in Calgary, Alberta at 10:00 a.m. (Calgary time) or such other time
as the Corporation may determine (the "Closing Time") on the Closing Date. The Corporation reserves the right
to close the Offering in multiple tranches, so that one or more closings may occur after the initial closing.

 

		9.	Subject to Regulatory Approval. The obligations of the parties hereunder are subject
to all required regulatory approvals being obtained.

 

		10.	Representations and Warranties of the Corporation. The Corporation hereby represents
and warrants to the Subscriber (and acknowledges that the Subscriber is relying thereon) that:

 

		(a)	the Corporation has the full corporate right, power and authority to execute and deliver this Subscription
Agreement and to issue the Common Shares to the Subscriber;

 

		(b)	the Corporation is duly incorporated and validly subsisting, and is qualified to carry on business
in each jurisdiction in respect of which the carrying out of the activities contemplated hereby make such qualification necessary;

 

		(c)	the Corporation has complied or will comply with all applicable corporate and securities laws in
connection with the offer and sale of the Common Shares;

 

		(d)	upon acceptance by the Corporation, this Subscription Agreement shall constitute a binding obligation
of the Corporation enforceable in accordance with its terms subject to applicable bankruptcy, insolvency, reorganization and other
laws of general application limiting the enforcement of creditors' rights generally and to the general principles of equity including
the fact that specific performance is available only in the discretion of the court;

 

		(e)	the execution, delivery and performance of this Subscription Agreement by the Corporation and the
issue of the Common Shares to the Subscriber pursuant hereto does not and will not constitute a breach of or default under the
constating documents of the Corporation, or any law, regulation, order or ruling applicable to the Corporation, or any agreement
to which the Corporation is a party or by which it is bound;

 

		(f)	the currently issued and outstanding Common Shares are listed and posted for trading on the TSX
Venture Exchange and no order ceasing or suspending trading in any securities of the Corporation has been issued or prohibiting
the sale of the Common Shares issuable pursuant to the terms of this Subscription Agreement and no proceedings for such purpose
are threatened or, to the best of the Corporation's knowledge, information and belief, pending;

 

		(g)	to its knowledge, the Corporation is not in default of any requirement of applicable securities
or corporate laws, regulations, orders, notices and policies and no securities commission has issued any order which is currently
outstanding preventing or suspending trading in the Common Shares or preventing the issuance of the Common Shares in accordance
with this Subscription Agreement; and

 

		(h)	the Corporation is a "reporting issuer" in each of British Columbia and Alberta and is
not included in a list of defaulting reporting issuers maintained by the securities commission in such provinces and in particular,
without limiting the foregoing, the Corporation has at all relevant times complied with its obligations to make timely disclosure
of all material changes relating to it, no such disclosure has been made on a confidential basis that is still maintained on a
confidential basis, and there is no material change relating to the Corporation which has occurred and with respect to which the
requisite material change report has not been filed with a securities commission in such provinces.

 

		11.	No Partnership. Nothing herein shall constitute or be construed to constitute a partnership
of any kind whatsoever between the Subscriber and the Corporation.

 

    	 

    	Zomedica Pharmaceuticals Corp.
Subscription Agreement for Common Shares
	 	Page 12 of 14

    

		12.	Governing Law. The contract arising out of acceptance of this Subscription Agreement
by the Corporation shall be governed by and construed in accordance with the laws of the Province of Alberta and the federal laws
of Canada applicable therein. The parties irrevocably attorn to the exclusive jurisdiction of the courts of the Province of Alberta.

 

		13.	Time of Essence. Time shall be of the essence of this Subscription Agreement.

 

		14.	Entire Agreement. This Subscription Agreement represents the entire agreement of
the parties hereto relating to the subject matter hereof, and there are no representations, covenants or other agreements relating
to the subject matter hereof except as stated or referred to herein.

 

		15.	Electronic Copies. The Corporation shall be entitled to rely on delivery of a facsimile
or other electronic copy of executed subscriptions, and acceptance by the Corporation of such facsimile or electronic copies shall
be legally effective to create a valid and binding agreement between the Subscriber and the Corporation in accordance with the
terms hereof.

 

		16.	Counterpart. This Subscription Agreement may be executed in one or more counterparts
each of which so executed shall constitute an original and all of which together shall constitute one and the same agreement.

 

		17.	Severability. The invalidity, illegality or unenforceability of any provision of
this Subscription Agreement shall not affect the validity, legality or enforceability of any other provision hereof.

 

		18.	Survival. The covenants, representations and warranties contained in this Subscription
Agreement shall survive the closing of the transactions contemplated hereby, and shall be binding upon and enure to the benefit
of the parties hereto and their respective heirs, executors, administrators, successors and permitted assigns.

 

		19.	Interpretation. The headings used in this Subscription Agreement have been inserted
for convenience of reference only and shall not affect the meaning or interpretation of this Subscription Agreement or any provision
hereof. In this Subscription Agreement, unless otherwise indicated, all references to money amounts are to Canadian dollars.

 

		20.	Amendment. Except as otherwise provided herein, this Subscription Agreement may only
be amended by the parties hereto in writing.

 

		21.	Costs. The Subscriber acknowledges and agrees that all costs incurred by the Subscriber
(including any fees and disbursements of any special counsel retained by the Subscriber) relating to the sale of the Common Shares
to the Subscriber shall be borne by the Subscriber.

 

		22.	Withdrawal. The Subscriber, on its own behalf and, if applicable, on behalf of others
for whom it is contracting hereunder, agrees that this subscription is made for valuable consideration and may not be withdrawn,
cancelled, terminated or revoked by the Subscriber, on its own behalf and, if applicable, on behalf of others for whom it is contracting
hereunder.

 

		23.	Assignment. Neither party may assign all or part of its interest in or to this Subscription
Agreement without the consent of the other party in writing.

 

		24.	Language. The Subscriber acknowledges that it has consented to and requested that
all documents evidencing or relating in any way to the sale of the Common Shares be drawn up in the English language only.

 

 

    	 

    	Zomedica Pharmaceuticals Corp.
Subscription Agreement for Common Shares
	 	Page 13 of 14

    

PRIVACY NOTICE

 

The Subscriber acknowledges that this Subscription Agreement and
the Exhibits hereto require the Subscriber to provide certain personal information to the Corporation. Such information is being
collected by the Corporation for the purposes of completing the Offering, which includes, without limitation, determining the Subscriber's
eligibility (or that of any Disclosed Beneficial Purchaser) to purchase the Common Shares under applicable securities laws, preparing
and registering certificates representing the Common Shares to be issued to the Subscriber and completing filings required by any
stock exchange or securities regulatory authority. In addition, such personal information may be used or disclosed by the Corporation
for the purpose of administering the Corporation's relationship with the Subscriber or, if applicable, the beneficial purchaser
for whom the Subscriber is contracting. For example, such personal information may be used by the Corporation to communicate with
the Subscriber or, if applicable, the beneficial purchaser for whom the Subscriber is contracting (such as by providing annual
or quarterly reports), to prepare tax filings and forms or to comply with its obligations under taxation, securities and other
laws (such as maintaining a list of holders of shares). The Subscriber's personal information (and that of any Disclosed Beneficial
Purchaser) may also be disclosed by the Corporation to (a) stock exchanges or securities regulatory authorities (including the
Ontario Securities Commission (the "OSC") and the British Columbia Securities Commission (the "BCSC")),
(b) the Corporation's registrar and transfer agent, (c) Canadian tax authorities, and (d) any of the other parties involved in
the Offering, including legal counsel, and may be included in closing books in connection with the Offering.

 

By executing this Subscription Agreement, the Subscriber (on its
own behalf and on behalf of any Disclosed Beneficial Purchaser for whom it is contracting hereunder) consents to the foregoing
collection, use and disclosure of the Subscriber's (and any Disclosed Beneficial Purchaser's) personal information. The Subscriber
(on its own behalf and on behalf of any Disclosed Beneficial Purchaser for whom it is contracting hereunder) also consents to the
filing of copies or originals of any of the Subscriber's documents delivered in connection with this Subscription Agreement as
may be required to be filed with any stock exchange or securities regulatory authority in connection with the transactions contemplated
hereby and expressly consents to the collection, use and disclosure of the Subscriber's (and any Disclosed Beneficial Purchaser's)
personal information by the TSX Venture Exchange or the Toronto Stock Exchange for the purposes identified by such exchange, from
time to time. The Subscriber (on its own behalf and on behalf of any Disclosed Beneficial Purchaser for whom it is contracting
hereunder) further acknowledges that it has been notified by the Corporation (a) of the requirement to deliver to the OSC and the
BCSC the full name, residential address and telephone number of the purchaser of the securities, the number and type of securities
purchased, the total purchase price, the exemption relied upon and the date of distribution; (b) that this information is being
collected indirectly by the OSC and BCSC under the authority granted to it in securities legislation; (c) that this information
is being collected for the purposes of the administration and enforcement of the securities legislation of Ontario and British
Columbia; (d) that the Administrative Support Clerk can be contacted at Ontario Securities Commission, Suite 1903, Box 55, 20 Queen
Street West, Toronto, Ontario, M5H 3S8, or at (416) 593-3684, and can answer any questions about the OSC's indirect collection
of this information; and (e) that the BCSC can be contacted at British Columbia Securities Commission, P.O. Box 10142, Pacific
Centre, 701 West Georgia Street, Vancouver, British Columbia, V7Y 1L2, Telephone: (604) 899-6500, Toll free across Canada: 1-800-373-6393,
Facsimile: (604) 899-658, and can answer any questions about the BCSC's indirect collection of this information.

 

    	 

    	Zomedica Pharmaceuticals Corp.
Subscription Agreement for Common Shares
	 	Page 14 of 14

    

TSX VENTURE EXCHANGE APPENDIX 6A

ACKNOWLEDGEMENT – PERSONAL INFORMATION

 

The Subscriber acknowledges as follows:

 

TSX Venture Exchange Inc. and its affiliates, authorized agents,
subsidiaries and divisions, including the TSX Venture Exchange (collectively referred to as "the Exchange") collect
Personal Information in certain Forms that are submitted by the individual and/or by an Issuer or Applicant and use it for
the following purposes:

 

		•	to
conduct background checks,

		•	to
verify the Personal Information that has been provided about each individual,

		•	to
consider the suitability of the individual to act as an officer, director, insider, promoter, investor relations provider or,
as applicable, an employee or consultant, of the Issuer or Applicant,

		•	to
consider the eligibility of the Issuer or Applicant to list on the Exchange,

		•	to
provide disclosure to market participants as to the security holdings of directors, officers, other insiders and promoters of
the Issuer, or its associates or affiliates,

		•	to
conduct enforcement proceedings, and

		•	to
perform other investigations as required by and to ensure compliance with all applicable rules,
policies, rulings and regulations of the Exchange, securities legislation and other legal and regulatory requirements governing
the conduct and protection of the public markets in Canada.

 

As part of this process, the Exchange
also collects additional Personal Information from other sources, including but not limited to, securities regulatory authorities
in Canada or elsewhere, investigative, law enforcement or self-regulatory organizations, regulations services providers and each
of their subsidiaries, affiliates, regulators and authorized agents, to ensure that the purposes set out above can be accomplished.

 

The Personal Information the Exchange collects may
also be disclosed:

 

		(a)	to the agencies and organizations in the preceding paragraph, or as otherwise permitted or required
by law, and they may use it in their own investigations for the purposes described above; and

 

		(b)	on the Exchange's website or through printed materials published by or pursuant to the directions
of the Exchange.

 

The Exchange may from time to time use third parties
to process information and/or provide other administrative services. In this regard, the Exchange may share the information with
such third party service providers

 

     

     

    

SCHEDULE "A"

 

 

 

 

REPRESENTATION LETTER

TO BE COMPLETED BY ACCREDITED INVESTORS

 

TO:               Zomedica Pharmaceuticals Corp. (the
"Corporation")

 

(Capitalized terms not specifically defined in this Schedule
have the meaning ascribed to them in the Subscription Agreement to which this Schedule is attached)

 

In connection with the execution by the undersigned Subscriber of
the Subscription Agreement which this Representation Letter forms a part of, the undersigned Subscriber hereby represents, warrants,
covenants and certifies to the Corporation and its counsel that:

 

		1.	the undersigned Subscriber is resident in the jurisdiction set out as the "Subscriber's Residential
Address" on the face page of the Subscription Agreement and, if the undersigned Subscriber is purchasing as agent for a disclosed
beneficial purchaser, the disclosed beneficial purchaser is resident in the jurisdiction set out as the "Disclosed Beneficial
Purchaser Information" on the face page of the Subscription Agreement;

 

		2.	the undersigned Subscriber is either (a) purchasing the Common Shares as principal for its own
account, (b) deemed to be purchasing the Common Shares as principal in accordance with section 2.3(2) or (4) of NI 45-106, or (c)
acting as agent for a disclosed beneficial purchaser who is purchasing the Common Shares as principal for its own account;

 

		3.	the undersigned Subscriber (or if the undersigned Subscriber is purchasing as agent for a disclosed
beneficial purchaser, the disclosed beneficial purchaser) is an "accredited investor" within the meaning of NI 45-106
and Section 73.3(1) of the Securities Act (Ontario), as applicable, by virtue of satisfying the indicated criterion as set
out in Exhibit A to this Representation Letter;

 

		4.	the Subscriber (or if the undersigned Subscriber is purchasing as agent for a disclosed beneficial
purchaser, the disclosed beneficial purchaser) fully understands the meaning of the terms and conditions of the category of "accredited
investor" applicable to it and confirms that it has reviewed and understands the definitions in Exhibit A to this Representation
Letter in respect of the category of "accredited investor" applicable to it and, in particular, if the Subscriber is
an "accredited investor" by virtue of satisfying paragraph (j), (j.1), (k) or (l) of Exhibit A to this Representation
Letter, it has reviewed and understands the definitions of "financial assets", "related liabilities" and "financial
assets", as applicable, contained in Exhibit A hereto;

 

		5.	the undersigned Subscriber (or if the undersigned Subscriber is purchasing as agent for a disclosed
beneficial purchaser, the disclosed beneficial purchaser) was not created, and is not used, solely to purchase or hold securities
as an accredited investor as described in paragraph (m) of the definition of "accredited investor" in NI 45-106;

 

		6.	if the Subscriber (or if the undersigned Subscriber is purchasing as agent for a disclosed beneficial
purchaser, the disclosed beneficial purchaser) is an "accredited investor" by virtue of satisfying paragraph (j), (k)
or (l) on Exhibit A to this Representation Letter, it acknowledges that it needs to complete Exhibit B to this Representation Letter
and upon execution of Exhibit B by the Subscriber, Exhibit B shall be incorporated into and form a part of this Representation
Letter and the Corporation and its counsel shall be entitled to rely thereon; and

 

    	 	A-1	 

     

    

		7.	upon execution of this Representation Letter by the undersigned Subscriber, this Representation
Letter, including the Exhibits hereto, shall be incorporated into and form a part of the Subscription Agreement.

 

 

 

	 	 	 
	 	Name of Subscriber (please print)	 
	 	 	 
	 	By:  	 
	 	 	
        Authorized Signature

         

         

	 	
        Official Title or Capacity (please print)

         

         

	 	Name of Signatory (please print name of individual whose signature appears above if different than name of Subscriber)
	 	 	 	 

 

 

DATED at _________________________ this ____ day of __________________________,
2016.

 

	IMPORTANT

PLEASE COMPLETE THE EXHIBITS TO THIS
REPRESENTATION LETTER

 

    	 	A-2	 

     

    

EXHIBIT A TO SCHEDULE "A"

 

TO BE COMPLETED BY ACCREDITED INVESTORS

 

PLEASE MARK
YOUR INITIALS BESIDE THE CATEGORY BELOW TO WHICH YOU BELONG

 

Please complete the Representation Letter to the Corporation by
marking your initials beside the category of "accredited investor" to which you belong within the meaning of Section
1.1 of NI 45-106 and Section 73.3(1) of the Securities Act (Ontario), as applicable:

 

Meaning of "Accredited Investor"

 

"Accredited investor" is defined in Section 1.1 of NI
45-106 to mean any person who fits within any of the following categories at the time of the sale of securities to that person:

 

	______		(a) (i) except in Ontario, a Canadian financial institution, or a bank listed in Schedule
III of the Bank Act (Canada),

 

		(ii)	in Ontario, (A) a bank listed in Schedule I, II or III to the Bank Act (Canada); (B) an
association to which the Cooperative Credit Associations Act (Canada) applies or a central cooperative credit
society for which an order has been made under subsection 473 (1) of that Act; or (C) a loan corporation, trust company, trust
corporation, insurance company, treasury branch, credit union, caisse populaire, financial services cooperative or credit union
league or federation that is authorized by a statute of Canada or Ontario to carry on business in Canada or Ontario, as the case
may be,

 

	______		(b) (i) except in Ontario, the Business Development Bank of Canada incorporated under
the Business Development Bank of Canada Act (Canada),

 

		(ii)	in Ontario, the Business Development Bank of Canada,

 

	______		(c) (i) except in Ontario, a subsidiary of any person referred to in paragraphs (a) or
                                                                                  (b), if the person owns all of the voting securities of the subsidiary, except the voting securities required by law to be
                                                                                  owned by directors of that subsidiary,

 

		(ii)	in Ontario, a subsidiary of any person referred to in paragraphs (a) through (e) above, if the
person owns all of the voting securities of the subsidiary, except the voting securities required by law to be owned by directors
of that subsidiary,

 

	______		(d) (i) except in Ontario, a person registered under the securities legislation of a
                                                                                  jurisdiction of Canada as an adviser or dealer,

 

		(ii)	in Ontario, a person or company registered under the securities legislation of a province or territory
of Canada as an adviser or dealer, except as otherwise prescribed by the regulations under the Securities Act (Ontario),

 

	______		(e) an individual registered under the securities legislation of a jurisdiction of Canada as
                                                                                  a representative of a person referred to in paragraph (d),

 

	______		(e.1) an individual formerly registered under the securities legislation of a jurisdiction
of Canada, other than an individual formerly registered solely as a representative of a limited market dealer under one or both
of the Securities Act (Ontario) or the Securities Act (Newfoundland and Labrador),

 

	______		(f) (i) except in Ontario, the Government of Canada or a jurisdiction of Canada, or any
                                                                                  crown corporation, agency or wholly owned entity of the government of Canada or a jurisdiction of Canada,

 

		(ii)	in Ontario, the Government of Canada, the government of a province or territory of Canada, or any
Crown corporation, agency or wholly owned entity of the Government of Canada or the government of a province or territory of Canada,

 

	______		(g) (i) except in Ontario, a municipality, public board or commission in Canada and a
                                                                                  metropolitan community, school board, the Comité de gestion de la taxe scolaire de l'île de Montréal or
                                                                                  an intermunicipal management board in Québec,

 

    	 	A-3	 

     

    

		(ii)	in Ontario, a municipality, public board or commission in Canada and a metropolitan community,
school board, the Comité de gestion de la taxe scolaire de l'île de Montréal or an intermunicipal management
board in Québec,

 

	______		(h) (i) except in Ontario, any national, federal, state, provincial, territorial or
                                                                                  municipal government of or in any foreign jurisdiction, or any agency of that government,

 

		(ii)	in Ontario, any national, federal, state, provincial, territorial or municipal government of or
in any foreign jurisdiction, or any agency of that government,

 

	______		(i) (i) except in Ontario, a pension fund that is regulated by either the Office of the
                                                                                  Superintendent of Financial Institutions (Canada) or a pension commission or similar regulatory authority of a
                                                                                  jurisdiction of Canada,

 

		(ii)	in Ontario, a pension fund that is regulated by the Office of the Superintendent of Financial Institutions
(Canada) or a pension commission or similar regulatory authority of a province or territory of Canada,

 

	______		(j) an individual who, either alone or with a spouse, beneficially owns, directly or
                                                                                  indirectly, financial assets having an aggregate realizable value that, before taxes, but net of any related liabilities,
                                                                                  exceeds $1,000,000,

 

[Note: Financial assets include cash and securities, but do
not include a personal residence – see the definition of "financial assets" later in this certificate. Financial
assets are generally liquid or relatively easy to liquidate. You must subtract any liabilities related to your financial assets
to calculate your net financial assets—see the definition of "related liabilities". Financial assets held in a
group RRSP under which you do not have the ability to acquire the financial assets and deal with them directly are not considered
to be beneficially owned by you. If you meet the higher financial asset threshold set out in paragraph (j.1), then initial paragraph
(j.1) instead of this paragraph (j).]

 

[Note: If you are an accredited investor described in this
paragraph (j), and do not meet the higher financial asset threshold set out in paragraph (j.1), you must deliver a completed Form
45-106F9 – Form for Individual Accredited Investors (See Exhibit B hereto).]

 

	______		(j.1) an individual who beneficially owns financial assets having an aggregate realizable
                                                                                  value that, before taxes but net of any related liabilities, exceeds $5,000,000,

 

[Note: The financial assets of your spouse (including financial
assets in a spousal RRSP) cannot be included in the calculation of net financial assets under this paragraph (j.1). See definition
of "financial assets" below. If you meet the financial asset threshold set out in this paragraph (j.1), you are not
required to complete Exhibit B.]

 

	______		(k) an individual whose net income before taxes exceeded $200,000 in each of the two most
                                                                                  recent calendar years or whose net income before taxes combined with that of a spouse exceeded $300,000 in each of the two
                                                                                  most recent calendar years and who, in either case, reasonably expects to exceed that net income level in the current
                                                                                  calendar year, [Note: You are required to complete Exhibit B]

 

[Note: If individual accredited investors wish to
purchase through wholly-owned holding companies or similar entities, such purchasing entities must qualify under section (t) below,
which must be initialed and complete. If you are an accredited investor described in this paragraph (k), you must deliver a completed
Form 45-106F9 – Form for Individual Accredited Investors (See Exhibit B hereto).]

 

	______		(l) an individual who, either alone or with a spouse, has net assets of at
                                                                                  least $5,000,000,

 

[Note: To calculate net assets, take the value of your total
assets (which may include a personal residence) and subtract your total liabilities (which may include a mortgage). The value attributed
to assets should reasonably reflect their estimated fair value. Income tax should be considered a liability if the obligation to
pay it is outstanding at the time of the subscription.]

 

[Note: If you are an accredited investor described in this
paragraph (l), you must deliver a completed Form 45-106F9 – Form for Individual Accredited Investors (See Exhibit B hereto).]

 

    	 	A-4	 

     

    

	______		(m) a person, other than an individual or an investment fund, that has net assets of at least
                                                                                 $5,000,000, as shown on its most recently prepared financial statements,

 

	______		(n) an investment fund that distributes or has distributed its securities only to:

 

		(i)	a person that is or was an accredited investor at the time of the distribution,

 

		(ii)	a person that acquires or acquired securities in the circumstances referred to in section 2.10
of National Instrument 45-106 (where the person subscribes for a minimum amount investment) and Section 2.19 of National Instrument
45-106 (where the person makes an additional investment in investment funds), or

 

		(iii)	a person described in paragraph (i) or (ii) that acquires or acquired securities under section
2.18 of National Instrument 45-106 (investment fund reinvestment),

 

	______		(o) an investment fund that distributes or has distributed securities under a prospectus in a
                                                                                  jurisdiction of Canada for which the regulator or, in Quebec, the securities regulatory authority, has issued a receipt,

 

	______		(p) a trust company or trust corporation registered or authorized to carry on business under
                                                                                  the Trust and Loan Companies Act (Canada) or under comparable legislation in a jurisdiction of Canada or a
                                                                                  foreign jurisdiction, acting on behalf of a fully managed account managed by the trust company or trust corporation, as the
                                                                                  case may be,

 

	______		(q) a person acting on behalf of a fully managed account managed by that person, if that
                                                                                  person is registered or authorized to carry on business as an adviser or the equivalent under the securities legislation of a
                                                                                  jurisdiction of Canada or a foreign jurisdiction,

 

	______		(r) a registered charity under the Income Tax Act (Canada) that, in regard to the
                                                                                  trade, has obtained advice from an eligibility adviser or an adviser registered under the securities legislation of
                                                                                  the jurisdiction of the registered charity to give advice on the securities being traded,

 

	______		(s) an entity organized in a foreign jurisdiction that is analogous to any of the entities
                                                                                  referred to in paragraphs (a) to (d) or paragraph (i) in form and function,

 

	______		(t) a person in respect of which all of the owners of interests, direct, indirect or
                                                                                  beneficial, except the voting securities required by law to be owned by directors, are persons that are accredited
                                                                                  investors,

 

Note: If you initialled (t), then indicate the name and category
of accredited investor (by reference to the applicable letter of this Exhibit A) of each of the owners of interests (attach additional
pages if more than three):

 

	 	Name

                                                                  
	 	Category of Accredited Investor
	 	
 

	 	
 

	 	
 

	 	
 

	 	
 

	 	
 

 

 

	______		(u) an investment fund that is advised by a person registered as an adviser or a person that
                                                                                  is exempt from registration as an adviser,

 

	______		(v) a person that is recognized or designated by the securities regulatory authority or,
                                                                                  except in Ontario and Québec, the regulator as an accredited investor, or

 

	______		(w) a trust established by an accredited investor for the benefit of the
                                                                                  accredited investor's family members of which a majority of the trustees are accredited investors and all of the
                                                                                  beneficiaries are the accredited investor's spouse, a former spouse of the accredited investor or a parent, grandparent,
                                                                                  brother, sister, child or grandchild of that accredited investor, of that accredited investor's spouse or of that accredited
                                                                                  investor's former spouse.

 

Note: If you initialed (w), then indicate the name and category
of accredited investor (by reference to the applicable letter of this Exhibit A) of each of the following (attach additional pages
if more than three trustees):

 

    	 	A-5	 

     

    

	 	 	Name	Category of Accredited Investor
	 	Individual who established trust:	
 

	
 

	 	Trustee	
 

	
 

	 	Trustee	
 

	
 

	 	Trustee	
 

	
 

	 	 	 	 

 

 

PLEASE MARK
YOUR INITIALS BESIDE THE CATEGORY ABOVE TO WHICH YOU BELONG

 

 

Interpretative Aids

 

The following definitions relate to certain of the categories set
forth above:

 

		(a)	"Canadian financial institution" means:

 

		(i)	an association governed by the Cooperative Credit Associations Act (Canada) or a central
cooperative credit society for which an order has been made under section 473(1) of that Act, or

 

		(ii)	a bank, loan corporation, trust company, trust corporation, insurance company, treasury branch,
credit union, caisse populaire, financial services cooperative, or league that, in each case, is authorized by an enactment of
Canada or a jurisdiction of Canada to carry on business in Canada or a jurisdiction of Canada;

 

		(b)	"Canadian securities regulatory authorities" means the securities commissions and similar
regulatory authorities of each of the provinces or territories of Canada;

 

		(c)	"eligibility adviser" means:

 

		(i)	a person that is registered as an investment dealer or in an equivalent category of registration
under the securities legislation of the jurisdiction of a purchaser and authorized to give advice with respect to the type of security
being distributed; and

 

		(ii)	in Saskatchewan or Manitoba, also means a lawyer who is a practicing member in good standing with
a law society of a jurisdiction of Canada or a public accountant who is a member in good standing of an institute or association
of chartered accountants, certified general accountants or certified management accountants in a jurisdiction of Canada provided
that the lawyer or public accountant must not:

 

		(A)	have a professional, business or personal relationship with the issuer, or any of its directors,
executive officers, founders, or control persons; and

 

		(B)	have acted for or been retained personally or otherwise as an employee, executive officer, director,
associate or partner of a person that has acted for or been retained by the issuer or any of its directors, executive officers,
founders or control persons within the previous 12 months;

 

		(d)	"EVCC" means an employee venture capital corporation that does not have a restricted
constitution, and is registered under Part 2 of the Employee Investment Act (British Columbia), R.S.B.C. 1996 c. 112, and
whose business objective is making multiple investments;

 

		(e)	"financial assets" means:

 

		(i)	cash;

 

		(ii)	securities; or

 

		(iii)	a contract of insurance, a deposit or an evidence of a deposit that is not a security for the purposes
of securities legislation;

 

		(f)	"foreign jurisdiction" means a country other than Canada or a political subdivision of
a country other than Canada;

 

		(g)	"fully managed account" means an account for which a person or company makes the investment
decisions if that person or company has full discretion to trade in securities for the account without requiring the client's express
consent to a transaction;

 

    	 	A-6	 

     

    

		(h)	"investment fund" means a mutual fund or a non-redeemable investment fund, and, for greater
certainty in British Columbia, includes an EVCC and a VCC;

 

		(i)	"jurisdiction" means a province or territory of Canada;

 

		(j)	"non-redeemable investment fund" means an issuer, (i) whose primary purpose is to invest
money provided by its securityholders; (ii) that does not invest (A) for the purpose of exercising or seeking to exercise control
of an issuer, other than an issuer that is a mutual fund or a non-redeemable investment fund, or (B) for the purpose of being actively
involved in the management of any issuer in which it invests, other than an issuer that is a mutual fund or a non-redeemable investment
fund; and (iii) that is not a mutual fund;

 

		(k)	"person" includes:

 

		(i)	an individual,

 

		(ii)	a corporation,

 

		(iii)	a partnership, trust, fund and an association, syndicate, organization or other organized group
of persons, whether incorporated or not, and

 

		(iv)	an individual or other person in that person's capacity as a trustee, executor, administrator or
personal or other legal representative;

 

		(l)	"related liabilities" means:

 

		(i)	liabilities incurred or assumed for the purpose of financing the acquisition or ownership of financial
assets, or

 

		(ii)	liabilities that are secured by financial assets;

 

		(m)	"securities legislation" means, for the local jurisdiction, the statute and other instruments
issued by the securities regulator authority of the local jurisdiction;

 

		(n)	"subsidiary" means an issuer that is controlled directly or indirectly by another issuer
and includes a subsidiary of that subsidiary; and

 

		(o)	"VCC" means a venture capital corporation registered under Part 1 of the Small Business
Venture Capital Act (British Columbia), R.S.B.C. 1996 c. 429 whose business objective is making multiple investments.

 

All monetary references in this Schedule "A" are in Canadian
dollars.

 

    	 	A-7	 

     

    

EXHIBIT B TO SCHEDULE "A"

FORM 45-106F9

FORM FOR INDIVIDUAL ACCREDITED INVESTORS

 

 

	WARNING!

 

This investment is risky. Don't invest
unless you can afford to lose all the money you pay for this investment.

 

	 
	SECTION 1 TO BE COMPLETED BY THE ISSUER OR SELLING SECURITYHOLDER:
	1. About your investment
	Type of securities:  Common Shares	Issuer:  Zomedica Pharmaceuticals Corp.
	
        Purchased from: Zomedica Pharmaceuticals Corp. (the Issuer
of the Common Shares)

         

	SECTIONS 2 TO 4 TO BE COMPLETED BY THE PURCHASER
	2. Risk acknowledgement
	This investment is risky. Initial that you understand that:	Your initials
	Risk of loss – You could lose your entire investment of $______________________. [Instruction: Insert the total dollar amount of the investment.]	 
	Liquidity risk – You may not be able to sell your investment quickly – or at all.	 
	Lack of information – You may receive little or no information about your investment.	 
	Lack of advice – You will not receive advice from the salesperson about whether this investment is suitable for you unless the salesperson is registered. The salesperson is the person who meets with, or provides information to, you about making this investment. To check whether the salesperson is registered, go to www.aretheyregistered.ca.	 
	3. Accredited investor status
	You must meet at least one of the following criteria to be able to make this investment. Initial the statement that applies to you. (You may initial more than one statement.) The person identified in section 6 is responsible for ensuring that you meet the definition of accredited investor. That person, or the salesperson identified in section 5, can help you if you have questions about whether you meet these criteria.	Your initials
	·   Your net income before taxes was more than $200,000 in each of the 2 most recent calendar years, and you expect it to be more than $200,000 in the current calendar year. (You can find your net income before taxes on your personal income tax return.)	 
	·   Your net income before taxes combined with your spouse's was more than $300,000 in each of the 2 most recent calendar years, and you expect your combined net income before taxes to be more than $300,000 in the current calendar year.	 
	·   Either alone or with your spouse, you own more than $1 million in cash and securities, after subtracting any debt related to the cash and securities.	 
	·   Either alone or with your spouse, you have net assets worth more than $5 million. (Your net assets are your total assets (including real estate) minus your total debt.)	 
	4. Your name and signature
	By signing this form, you confirm that you have read this form and you understand the risks of making this investment as identified in this form.
	First and last name (please print):
	Signature:	Date:
	 	 	 	 	 	 	 

 

    	 	A-8	 

     

    

	SECTION 5 TO BE COMPLETED BY THE SALESPERSON
	5. Salesperson information
	[Instruction: The salesperson is the person who meets with, or provides information to, the purchaser with respect to making this investment. That could include a representative of the issuer or selling security holder, a registrant or a person who is exempt from the registration requirement.]
	First and last name of salesperson (please print):
	Telephone:	Email:
	Name of firm (if registered):
	SECTION 6 TO BE COMPLETED BY THE ISSUER OR SELLING SECURITY HOLDER
	6. For more information about this investment
	
        For investment in a non-investment fund

         

        Zomedica Pharmaceuticals Corp.

        3928 Varsity Drive, Ann Arbor Michigan 48108  

        Gerald Solensky Jr.  

        734-369-2555  

        gsolensky@zomedica.com 

        Zomedica.com   

         

        For more information about prospectus exemptions, contact your local
        securities regulator. You can find contact information at www.securities-administrators.ca.

         

	 	 	 	 	 	 	 

 

Form instructions:

 

		1.	This form does not mandate the use of a specific font size or style but the font must be legible.

 

		2.	The information in sections 1, 5 and 6 must be completed before the purchaser completes and signs
the form.

 

		3.	The purchaser must sign this form. Each of the purchaser and the issuer or selling security
holder must receive a copy of this form signed by the purchaser. The issuer or selling security holder is required to keep a copy
of this form for 8 years after the distribution.

 

    	 	A-9	 

     

    

SCHEDULE "B"

 

 

REPRESENTATION LETTER

 

TO BE COMPLETED BY SUBSCRIBERS WHO ARE FAMILY MEMBERS, CLOSE
PERSONAL FRIENDS OR CLOSE PERSONAL BUSINESS ASSOCIATES (EXCEPT FOR RESIDENTS OF ONTARIO)

 

TO:                     Zomedica Pharmaceuticals Corp. (the
"Corporation")

 

(Capitalized terms not specifically defined in this Schedule
have the meaning ascribed to them in the Subscription Agreement to which this Schedule is attached)

 

In connection with the execution by the undersigned Subscriber of
the Subscription Agreement which this Representation Letter forms a part of, the undersigned Subscriber hereby represents, warrants,
covenants and certifies to the Corporation that:

 

		1.	The Subscriber is resident in the jurisdiction described on the face page of this Subscription
Agreement, other than Ontario;

 

		2.	The Subscriber is purchasing the Common Shares as principal for its own account;

 

		3.	In connection with the purchase of Common Shares of the Corporation by the Subscriber, the Subscriber
hereby represents and warrants that the Subscriber is:

 

	☐	(a)a director, executive officer or control person of the Corporation or an affiliate of the Corporation;
	☐	(b)a spouse, parent, grandparent, brother, sister or child of a director, executive officer or control person of the Corporation, or affiliate of the Corporation;
	☐	(c)a parent, grandparent, brother, sister or child of the spouse of a director, executive officer or control person of the Corporation, or affiliate of the Corporation;
	☐	(d)a close personal friend of director, executive officer or control person of the Corporation, or affiliate of the Corporation;
	☐	(e)a close business associate of director, executive officer or control person of the Corporation, or affiliate of the Corporation;
	☐	(f)a founder of the Corporation or a spouse, parent, grandparent, brother, sister, child close personal friend or close business associate of a founder of the Corporation;
	☐	(g)a parent, grandparent, brother, sister or child of the spouse of a founder of the Corporation;
	☐	(h)a person of which a majority of the voting securities are beneficially owned by, or a majority of the directors are, persons described in paragraphs (a) to (g); or
	☐	(i)a trust or estate of which all of the beneficiaries or a majority of the trustees or executors are persons described in paragraphs (a) to (g).

 

PLEASE MARK
YOUR INITIALS BESIDE THE CATEGORY TO WHICH YOU BELONG

 

 

Please briefly describe the nature of the relationship and name
of the person to whom you are related:

 

 

 

 

 

 

 

    	 	B-1	 

     

    

Interpretive Aids

 

"Close Personal Friend" is an individual who has
known the director, executive officer, founder or control person well enough and for a sufficient period of time to be in a position
to assess their capabilities and trustworthiness. The term "close personal friend" can include family members not already
specifically identified in the exemption if the family member satisfies the criteria described above. An individual is not a close
personal friend solely because the individual is a relative; a member of the same club, organization, association or religious
group; a co-worker, colleague or associate at the same workplace; a client, customer or former client or customer; a mere acquaintance;
or connected through some form of social media such as Facebook, Twitter or LinkedIn. The relationship between the purchaser and
director, executive officer, founder or control person must be direct. For example, the exemption is not available for a close
personal friend of a close personal friend of the director, executive officer, founder or control person.

 

"Close Business Associate" is an individual who
has had sufficient prior business dealings with the director, executive officer, founder or control person to be in a position
to assess their capabilities and trustworthiness. An individual is not a close business associate solely because the individual
is a member of the same club, organization, association or religious group; a co-worker, colleague or associate at the same workplace;
a client, customer or former client or customer; a mere acquaintance; or connected through some form of social media such as Facebook,
Twitter or LinkedIn. The relationship between the purchaser and director, executive officer, founder or control person must be
direct. For example, the exemption is not available for a close business associate of a close business associate of a director,
executive officer, founder or control person.

 

"Control Person" means any person that holds or
is one of a combination of persons that holds: (a) a sufficient number of any of the securities of the Corporation so as to
affect materially the control of the Corporation; or (b) more than 20% of the voting shares of the Corporation except where there
is evidence showing the holding of the shares does not affect materially the control of the Corporation.

 

"Executive Officer" means, for the Corporation,
an individual who is:

 

		(a)	a chair, vice-chair or president;

 

		(b)	a vice-president in charge of a principal business unit, division or function including sales,
finance or production,

 

		(c)	an officer of the Corporation or any of its subsidiaries and who performs a policy-making function
in respect of the Corporation, or

 

		(d)	performing a policy-making function in respect of the Corporation.

 

"Founder" means a person or company who,

 

		(a)	acting alone, in conjunction or in concert with one or more other persons or companies, directly
or indirectly, takes the initiative in founding, organizing or substantially reorganizing the business of the Corporation, and

 

		(b)	at the time of the proposed trade, is actively involved in the business of the Corporation.

 

"Person" includes:

 

		(a)	an individual;

 

		(b)	a corporation;

 

		(c)	a partnership, trust, fund and an association, syndicate, organization or other organized group
of persons, whether incorporated or not; and

 

		(d)	an individual or other person in that person's capacity as a trustee, executor, administrator or
personal or other legal representative.

 

	 	 	 
	 	Name of Subscriber (please print)	 
	 	 	 
	 	By:  	 
	 	 	
        Authorized Signature

         

	 	
        Official Title or Capacity (please print)

         

	 	
        Name of Signatory (please print name of individual
whose signature appears above different than name of Subscriber)

	 	 	 	 

 

DATED at _________________________ this _______ day of ______,
2016.

 

    	 	B-2	 

     

    

SCHEDULE "C"

 

 

RISK ACKNOWLEDGEMENT FORM

 

TO BE COMPLETED BY SUBSCRIBERS RESIDENT IN SASKATCHEWAN

WHO ARE FAMILY MEMBERS, CLOSE PERSONAL FRIENDS OR CLOSE PERSONAL
BUSINESS ASSOCIATES BUT ARE NOT ACCREDITED INVESTORS AS PER SCHEDULE "A"

 

	
        Risk Acknowledgement Form

        Saskatchewan Close Personal Friends and Close Business
Associates

         

        I acknowledge this is a risky investment:

         

	I am investing entirely at my own risk.
	No securities regulatory authority or regulator has evaluated or endorsed the merits of these securities.
	The person selling me these securities is not registered with a securities regulatory authority or regulator
        and has no duty to tell me whether this investment is suitable for me.
	I will not be able to sell these securities for 4 months.
	I could lose all the money I invest.
	I do not have a 2-day right to cancel my purchase of these securities or the statutory rights of action
        for misrepresentation I would have if I were purchasing the securities under a prospectus. I do have a 2-day right to cancel my
        purchase of these securities if I receive an amended offering document.

         

        I am investing $____________ [total consideration] in total; this
        includes any amount I am obliged to pay in future.

         

        I am a close personal friend or close business associate
        of ______________________ [state name], who is a ______________________ [state title – founder, director, senior officer
        or control person] of Zomedica Pharmaceuticals Corp. or its affiliate ________________________.

         

        I acknowledge that I am purchasing based on my close relationship
        with _________________ [state name of founder, director, senior officer or control person] whom I know well enough and for a sufficient
        period of time to be able to assess her/his capabilities and trustworthiness.

         

        I acknowledge that this is a risky investment and that I could
        lose all the money I invest.

         

        _____________________
                      _____________________________

        

        Date                                                 Signature
of Purchaser

         

                                                                 _____________________________

                                                                 Print
name of Purchaser

         

        Sign 2 copies of this document. Keep one copy for your
records.

         
	 

 

    	 	C-1	 

     

    

You are buying Exempt Market Securities

 

They are called exempt market securities because
two parts of securities law do not apply to them. If an issuer wants to sell exempt market securities to you:

 

		·	the issuer does not have to give you a prospectus (a document that describes the investment in
detail and gives you some legal protections), and

 

		·	the securities do not have to be sold by an investment dealer registered with a securities regulatory
authority.

 

There are restrictions on your ability to resell exempt
market securities. Exempt market securities are more risky than other securities.

 

You may not receive any written information about the
issuer or its business

 

If you have any questions about the issuer or its business,
ask for written clarification before you purchase the securities. You should consult your own professional advisers before investing
in the securities.

 

You will not receive advice 

 

Unless you consult your own professional advisers, you
will not get professional advice about whether the investment is suitable for you.

 

For more information on the exempt market, refer to the
Saskatchewan Financial Services Commission's website at http://www.sfsc.gov.sk.ca.

 

[Instruction: The purchaser must sign 2 copies of
this form. The purchaser and the issuer must each receive a signed copy.]

 

    	 	C-2	 

     

    

SCHEDULE "D"

 

Ontario Investors Only

 

FORM 45-106F12

RISK ACKNOWLEDGEMENT FORM FOR ONTARIO FAMILY, FRIENDS
AND BUSINESS ASSOCIATES

 

WARNING!

This investment is risky. Don't invest unless you can afford to lose all the money you pay 

for this investment

 

 

	SECTION 1 TO BE COMPLETED BY THE ISSUER
	1. About your investment
	Type of securities:  Common Shares	Issuer:  Zomedica Pharmaceuticals Corp.
	
        Purchased from: Zomedica Pharmaceuticals Corp. (the Issuer
of the Common Shares)

         

	SECTIONS 2 TO 4 TO BE COMPLETED BY THE PURCHASER
	2. Risk acknowledgement [Instruction: initial all boxes in Section 2]
	This investment is risky. Initial that you understand that:	Your initials
	
        Risk of loss – You could lose your
entire investment of $______________________. [Instruction: Insert

        the total dollar amount of the investment.]

         
	 
	Liquidity risk – You may not be able to sell your investment quickly – or at all.	 
	
        Lack of information – You may receive
little or no information about your investment. The information you receive may be limited to the information provided to you
by the family member, friend or close business associate specified in section 3 of this form.

         
	 
	 	 
	3. Family, friend or business associate status [Instruction: initial one or more boxes that apply]
	You must meet at least one of the following criteria to be able to make this investment. Initial the statement that applies to you.	Your initials
	
        A) You are:

         

        1. [check all applicable boxes]

         

        [_] a director of the issuer or an affiliate of the issuer

         

        [_] an executive officer of the issuer or an affiliate
        of the issuer

         

        [_] a control person of the issuer or an affiliate of
        the issuer

         

        [_] a founder of the issuer

         

        OR

         
	 
	                                                               
	 	 	 	 	 	 

 

    	 	D-1	 

     

    

		 
	
        2. [check all applicable boxes]

         

        [_] a person of which a majority of the voting securities
        are beneficially owned by, or a majority of the directors are, (i) individuals listed in (1) above and/or (ii) family members,
        close personal friends or close business associates of individuals listed in (1) above

         

        [_] a trust or estate of which all of the beneficiaries
        or a majority of the trustees or executors are (i) individuals listed in (1) above and/or (ii) family members, close personal friends
        or close business associates of individuals listed in (1) above

         
	 
	B) You are a family member of ____________________
        [Instruction: Insert the name of the person who is your relative either directly or through his or her spouse], who holds
        the following position at the issuer or an affiliate of the issuer: ____________________.

         

        You are the ____________________ of that
        person or that person's spouse.

         

        [Instruction: To qualify for this investment,
        the person listed above must be (a) your spouse or (b) your or your spouse's parent, grandparent, brother, sister, child
        or grandchild.]

         
	                       
	
        C) You are a close personal friend of ____________________
        [Instruction: Insert the name of your close personal friend], who holds the following position at the issuer or an affiliate
        of the issuer: ____________________.

         

        You have known that person for _____ years.

         
	 
	
        D) You are a close business associate of ____________________
        [Instruction: Insert the name of your close business associate], who holds the following position at the issuer or an affiliate
        of the issuer: ____________________.

         

        You have known that person for _____ years.

         
	 
	4. Your name and signature
	By signing this form, you confirm that you have read this form and you understand the risks of making this investment as identified in this form. You also confirm that you are eligible to make this investment because you are a family member, close personal friend or close business associate of the person identified in section 5 of this form.
	First and last name (please print):
	Signature:	Date:
	SECTION 5 TO BE COMPLETED BY PERSON WHO CLAIMS THE CLOSE PERSONAL RELATIONSHIP, IF APPLICABLE
	5. Contact person at the issuer or an affiliate of the issuer
	[Instruction: To be completed by the director, executive officer, control person or founder with whom the purchaser has a close personal relationship indicated under sections 3B, C or D of this form.]
	
        By signing this form, you confirm that you have,
        or your spouse has, the following relationship with the purchaser: [check the box that applies]

         

        [_] family relationship as set out in section
3B of this form 

        [_] close personal friendship as set out
in section 3C of this form 

        [_] close business associate relationship as set
        out in section 3D of this form

         

	First and last name of contact person (please print):
	Position with the issuer or affiliate of the issuer (director, executive officer, control person or founder):
	Telephone:	Email:
	 	 	 	 	 	 

 

    	 	D-2	 

     

    

	Signature:	Date:
	SECTION 6 TO BE COMPLETED BY THE ISSUER
	6. For more information about this investment
	
        Zomedica Pharmaceuticals Corp.

         

        3928 Varsity Drive, Ann Arbor Michigan 48108

        Attention: Gerald Solensky Jr.

        Phone: 734-369-2555

        e-mail: gsolensky@zomedica.com

        Website: Zomedica.com

         

	For more information about prospectus exemptions, contact your local securities regulator.  You can find contact information at www.securities-administrators.ca. 

                                                                                 
	Signature of executive officer of the issuer (other than the purchaser):	Date:
	 	 	 	 	 	 	 

 

 

Form instructions:

 

		1.	The information in sections 1, 5 and 6 must be completed before the purchaser completes
and signs the form.

 

		2.	The purchaser, an executive officer who is not the purchaser and, if applicable, the person
who claims the close personal relationship to the purchaser must sign this form. Each of the purchaser, contact person at the issuer
and the issuer must receive a copy of this form signed by the purchaser. The issuer is required to keep a copy of this form for
8 years after the distribution.

 

		3.	The detailed relationships required to purchase securities under this exemption are set out
in section 2.5 of National Instrument 45-106 Prospectus Exemptions. For guidance on the meaning of "close personal friend"
and "close business associate", please refer to sections 2.7 and 2.8, respectively, of Companion Policy 45-106CP Prospectus
Exemptions.

 

    	 	D-3	 

     

    

SCHEDULE "E"

 

 

REPRESENTATION LETTER

(FOR NON-CANADIAN RESIDENT INVESTORS ONLY, EXCLUDING U.S. PURCHASERS)

 

		TO:	Zomedica Pharmaceuticals Corp. (the "Corporation")

 

(Capitalized terms not specifically defined in this Schedule
have the meaning ascribed to them in the Subscription Agreement to which this Schedule is attached)

 

In connection with the execution by the undersigned Subscriber of
the Subscription Agreement which this Representation Letter forms a part of, the undersigned Subscriber hereby represents, warrants,
covenants and certifies to the Corporation that:

 

		1.	The undersigned Subscriber and (if applicable) any other purchaser for whom it is acting hereunder,
is resident in the jurisdiction set out as the "Subscriber's Residential Address" on the face page of the Subscription
Agreement (the "Foreign Jurisdiction") and the undersigned Subscriber certifies that it and (if applicable) any other
purchaser for whom it is acting hereunder is not resident in or otherwise subject to applicable securities laws of any province
or territory of Canada.

 

		2.	The undersigned Subscriber and (if applicable) any other purchaser for whom it is acting hereunder,
is a purchaser which is purchasing the Common Shares pursuant to an exemption from any prospectus or securities registration or
similar requirements under the applicable securities laws of the Foreign Jurisdiction or any other securities laws to which the
Subscriber and (if applicable) any other purchaser for whom the Subscriber is acting hereunder are otherwise subject.

 

		3.	The purchase of Common Shares by the Subscriber, and any other purchaser for whom it is acting
hereunder, does not contravene any of the applicable securities laws in the Foreign Jurisdiction or any other securities laws to
which the Subscriber and (if applicable) any other purchaser for whom the Subscriber is acting hereunder are otherwise subject
and does not result in: (i) any obligation of the Corporation to prepare and file a prospectus, an offering memorandum or similar
document; or (ii) any obligation of the Corporation to make any filings with or seek any approvals of any kind from any regulatory
body in such jurisdiction or any other ongoing reporting requirements with respect to such purchase or otherwise; or (iii) any
registration or other obligation on the part of the Corporation under the applicable securities laws in the Foreign Jurisdiction
or any other securities laws to which the Subscriber and (if applicable) any other purchaser for whom the Subscriber is acting
hereunder are otherwise subject.

 

		4.	The Common Shares are being acquired for investment purposes only and not with a view to the resale
or distribution of all or any of the Common Shares.

 

		5.	The undersigned Subscriber and (if applicable) any other purchaser for whom it is acting hereunder,
are knowledgeable of, and have been independently advised as to, the securities laws of the Foreign Jurisdiction or any other securities
laws to which the Subscriber and (if applicable) any other purchaser for whom the Subscriber is acting hereunder are otherwise
subject.

 

		6.	The undersigned Subscriber and (if applicable) any other purchaser for whom it is acting hereunder,
is aware that its ability to enforce civil liabilities under applicable securities laws may be affected adversely by, among other
things: (A) the fact that the Corporation is organized under the laws of a province of Canada; (B) some or all of the directors
and officers may be residents of Canada; and (C) all or a substantial portion of the assets of the Corporation and said persons
may be located outside the Foreign Jurisdiction.

 

    	 	E-1	 

     

    

		7.	Upon execution of this Schedule by the undersigned Subscriber, this Representation Letter shall
be incorporated into and form a part of the Subscription Agreement.

 

Dated: _________________________, 2016.

 

 

 

________________________________________

Print name of Subscriber

 

 

By: ____________________________________

       Signature

 

_______________________________________

Print name of Signatory (if different from the Subscriber)

 

_______________________________________

Title

 

 

 

 

    	 	E-2	 

     

    

SCHEDULE "F"

  

PROVISIONS APPLICABLE
TO A U.S. PURCHASER

CERTIFICATION OF U.S.
PURCHASER

 

NOTE: the provisions on this page are applicable ONLY if the
Purchaser was offered the Common Shares while in the United States or was in the United States at the time the buy order was originated
or the Subscription Agreement to which this Schedule is attached was executed or delivered.

 

TO:                         Zomedica Pharmaceuticals Corp. (the
"Corporation")

 

(Capitalized terms not specifically defined in this Certification
have the meaning ascribed to them in the Subscription Agreement to which this Schedule is attached.)

 

In connection with the execution of the Subscription Agreement to
which this Schedule is attached, the undersigned (the "Purchaser") represents, warrants and covenants (which representations,
warranties and covenants shall survive the Closing Date) to the Corporation (and acknowledges that the Corporation is relying thereon)
that:

 

		(a)	It, alone or with the assistance of its professional advisors, has such knowledge and experience
in financial and business matters as to be capable of evaluating the merits and risks of the investment and it is able to bear
the economic risk of loss of the investment in the Common Shares and is able, without impairing its financial condition, to hold
the Common Shares for an indefinite period of time and to bear the economic risks, and withstand a complete loss, of such investment;

 

		(b)	it is authorized to consummate the purchase of the Common Shares;

 

		(c)	the Corporation has provided to it the opportunity to ask questions and receive answers concerning
the terms and conditions of the Offering and it has had access to such information concerning the Corporation as it has considered
necessary or appropriate in connection with its investment decision to acquire the Common Shares, including access to the Corporation's
public filings available on the Internet at www.sedar.com, and that any answers to questions and any request for information have
been complied with to the Purchaser's satisfaction;

 

		(d)	it is purchasing the Common Shares for its own account or for the account of one or more persons
for whom it is exercising sole investment discretion, (a "Beneficial Purchaser"), for investment purposes only and not
with a view to resale or distribution in violation of applicable securities laws and, in particular, neither it nor any Beneficial
Purchaser for whose account it is purchasing the Common Shares has any intention to distribute either directly or indirectly any
of the Common Shares in the United States; provided, however, that this paragraph shall not restrict the Purchaser from selling
or otherwise disposing of any of the Common Shares pursuant to registration thereof pursuant to the United States Securities Act
of 1933, as amended (the "U.S. Securities Act"), and any applicable state securities laws or under an exemption from
such registration requirements;

 

		(e)	it, and if applicable, each Beneficial Purchaser for whose account it is purchasing the Common
Shares is an "accredited investor" as defined in Rule 501(a) of Regulation D under the U.S. Securities Act ("U.S.
Accredited Investor") and, as such, satisfies one or more of the categories of U.S. Accredited Investor indicated below and
acknowledges that the offer and sale of the Common Shares to it is being made in reliance upon Rule 506(b) of Regulation D under
the U.S. Securities Act (the Purchaser must initial "SUB" for the Purchaser, and "BP" for each Beneficial
Purchaser, if any, on the appropriate line(s)):

 

	 	 	 	Category 1. 	A bank, as defined in Section 3(a)(2) of the U.S. Securities Act, whether
acting in its individual or fiduciary capacity; or
	 	 	 	 	 
	 	 	 	Category 2.	A savings and loan association or other institution as defined in Section
3(a)(5)(A) of the U.S. Securities Act, whether acting in its individual or fiduciary capacity; or
	 	 	 	 	 
	 	 	 	Category 3.	A broker or dealer registered pursuant to Section 15 of the United
States Securities Exchange Act of 1934, as amended; or
	 	 	 	 	 
	 	 	 	Category 4.	An insurance company as defined in Section 2(13) of the U.S. Securities
Act; or

 

    	 	F-1	 

     

    

 

	 	 	 	Category 5. 	An investment company registered under the United States Investment
Company Act of 1940, as amended; or
	 	 	 	 	 
	 	 	 	Category 6.	A business development company as defined in Section 2(a)(48) of the
United States Investment Company Act of 1940, as amended; or
	 	 	 	 	 
	 	 	 	Category 7.	A small business investment company licensed by the U.S. Small Business
Administration under Section 301 (c) or (d) of the United States Small Business Investment Act of 1958, as amended; or
	 	 	 	 	 
	 	 	 	Category 8.	A plan established and maintained by a state, its political subdivisions
or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, with total assets
in excess of U.S. $5,000,000; or
	 	 	 	 	 
	 	 	 	Category 9.	An employee benefit plan within the meaning of the United States Employee
Retirement Income Security Act of 1974, as amended, in which the investment decision is made by a plan fiduciary, as defined in
Section 3(21) of such Act, which is either a bank, savings and loan association, insurance company or registered investment
adviser, or an employee benefit plan with total assets in excess of U.S. $5,000,000 or, if a self-directed plan, with investment
decisions made solely by persons who are "accredited investors" as such term is defined in Rule 501(a) of Regulation
D under the U.S. Securities Act; or
	 	 	 	 	 
	 	 	 	Category 10.	A private business development company as defined in Section 202(a)(22)
of the United States Investment Advisers Act of 1940, as amended; or
	 	 	 	 	 
	 	 	 	Category 11.	An organization described in Section 501(c)(3) of the United States
Internal Revenue Code of 1986, as amended, a corporation, a Massachusetts or similar business trust, a limited liability company
or a partnership, not formed for the specific purpose of acquiring the securities offered, with total assets in excess of U.S.
$5,000,000; or
	 	 	 	 	 
	 	 	 	Category 12.	Any director or executive officer of the Corporation; or
	 	 	 	 	 
	 	 	 	Category 13.	A natural person whose individual net worth, or joint net worth with
that person's spouse, at the date hereof exceeds U.S.$1,000,000 (Note: For purposes of calculating "net worth"
under this paragraph: (i) the person's primary residence shall not be included as an asset; (ii) indebtedness that is secured
by the person's primary residence, up to the estimated fair market value of the primary residence at the time of the sale of securities,
shall not be included as a liability (except that if the amount of such indebtedness outstanding at the time of the sale of securities
exceeds the amount outstanding 60 days before such time, other than as a result of the acquisition of the primary residence, the
amount of such excess shall be included as a liability); and (iii) indebtedness that is secured by the person's primary residence
in excess of the estimated fair market value of the primary residence at the time of the sale of securities shall be included
as a liability.); or
	 	 	 	 	 
	 	 	 	Category 14.	A natural person who had an individual income in excess of U.S. $200,000
in each of the two most recent years or joint income with that person's spouse in excess of U.S. $300,000 in each of those years
and has a reasonable expectation of reaching the same income level in the current year; or
	 	 	 	 	 
	 	 	 	Category 15.	A trust, with total assets in excess of U.S. $5,000,000, not formed
for the specific purpose of acquiring the securities offered, whose purchase is directed by a sophisticated person as described
in Rule 506(b)(2)(ii) under the U.S. Securities Act; or
	 	 	 	 	 
	 	 	 	Category 16.	Any entity in which all of the equity owners meet the requirements
of at least one of the above categories;

 

		(f)	it understands and acknowledges that upon the original issuance thereof, and until such time as
the same is no longer required under the applicable requirements of the U.S. Securities Act or applicable U.S. state securities
laws, the certificates representing the Common Shares, and all certificates issued in exchange therefor or in substitution thereof,
will bear a legend in substantially the following form:

 

    	 	F-2	 

     

    

"THE SECURITIES REPRESENTED HEREBY HAVE NOT
BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "U.S. SECURITIES ACT"),
OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE HOLDER HEREOF, BY PURCHASING THESE SECURITIES, AGREES FOR THE BENEFIT
OF ZOMEDICA PHARMACEUTICALS CORP. (THE "COMPANY") THAT THESE SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED
ONLY (A) TO THE COMPANY, (B) OUTSIDE THE UNITED STATES IN ACCORDANCE WITH RULE 904 OF REGULATION S ("REGULATION S")
UNDER THE U.S. SECURITIES ACT AND IN COMPLIANCE WITH APPLICABLE LOCAL LAWS AND REGULATIONS, (C) IN COMPLIANCE WITH THE EXEMPTION
FROM REGISTRATION UNDER THE U.S. SECURITIES ACT PROVIDED BY (1) RULE 144 THEREUNDER, IF AVAILABLE, OR (2) RULE 144A THEREUNDER,
IF AVAILABLE,, AND, IN BOTH CASES, IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS, (D) IN ANOTHER TRANSACTION THAT DOES NOT
REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAWS, OR (E) PURSUANT TO A REGISTRATION
STATEMENT THAT HAS BEEN DECLARED EFFECTIVE UNDER THE U.S. SECURITIES ACT, AND, IN THE CASE OF (C)(1) AND (D) ABOVE, AFTER THE
SELLER FURNISHES TO THE COMPANY AN OPINION OF COUNSEL OF RECOGNIZED STANDING IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO
THE COMPANY TO SUCH EFFECT. DELIVERY OF THIS CERTIFICATE MAY NOT CONSTITUTE "GOOD DELIVERY" IN SETTLEMENT OF TRANSACTIONS
ON STOCK EXCHANGES IN CANADA.";

 

provided that, if any Common Shares are being
sold in compliance with Rule 904 of Regulation S, as referred to above, and in compliance with local laws and regulations, the
legend may be removed by providing to Computershare Trust Company of Canada (i) a declaration in the form attached hereto as Appendix
A (or as the Corporation may prescribe from time to time);

 

notwithstanding the foregoing, Computershare
Trust Company of Canada may impose additional requirements for the removal of legends from securities sold in accordance with Rule
904 of Regulation S in the future;

 

and provided, further, that, if any Common
Shares are being sold pursuant to Rule 144 of the U.S. Securities Act, the legend may be removed by delivering to the Corporation
and Computershare Trust Company of Canada an opinion of counsel of recognized standing in form and substance reasonably satisfactory
to the Corporation to the effect that the legend is no longer required under applicable requirements of the U.S. Securities Act
or state securities laws;

 

		(g)	it understands and acknowledges that the Common Shares have not been and will not be registered
under the U.S. Securities Act or the securities laws of any state of the United States, and the Common Shares are, or will when
issued be, "restricted securities" within the meaning of Rule 144 under the U.S. Securities Act, and it agrees that if
it decides to resell, pledge or otherwise transfer any of the Common Shares, it will not resell, pledge or otherwise transfer any
such securities, directly or indirectly, unless the transfer is made: (i) to the Corporation, (ii) outside the United States in
accordance with the requirements of Rule 904 of Regulation S under the U.S. Securities Act and in compliance with applicable local
laws and regulations, (iii) in compliance with the exemption from registration under the U.S. Securities Act provided by (A) Rule
144 thereunder, if available, or (B) Rule 144A thereunder, if available, (iv) in another transaction that does not require registration
under the U.S. Securities Act or any applicable state securities laws, or (v) pursuant to a registration statement that has been
declared effective under the U.S. Securities Act, and, in each case in compliance with applicable securities laws of any state
of the United States, and, in the case of (iii)(A) and (iv) above, after it has furnished to the Corporation an opinion of counsel
of recognized standing in form and substance reasonably satisfactory to the Corporation to such effect;

 

		(h)	it consents to the Corporation making a notation on its records or giving instructions to the transfer
agent for the Common Shares in order to implement the restrictions on transfer set forth and described herein;

 

		(i)	it understands and acknowledges that (i) if the Corporation is deemed to have been at any time
previously an issuer with no or nominal operations and no or nominal assets other than cash and cash equivalents, Rule 144 under
the U.S. Securities Act may not be available for resales of the Common Shares and (ii) the Corporation is not obligated to make
Rule 144 under the U.S. Securities Act available for resales of such Common Shares;

 

    	 	F-3	 

     

    

		(j)	it understands and acknowledges that the Corporation has no obligation or present intention of
filing with the United States Securities and Exchange Commission (the "SEC") or with any state securities administrator
any registration statement in respect of resales of the Common Shares in the United States;

 

		(k)	(i) the funds representing the Aggregate Subscription Amount which will be advanced by the undersigned
to the Corporation will not represent proceeds of crime for the purposes of the United States Uniting and Strengthening America
by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act (the "PATRIOT Act"), and the undersigned
acknowledges that the Corporation may in the future be required by law to disclose the undersigned's name and other information
relating to the Subscription Agreement to which this Schedule is attached and the undersigned's subscription hereunder, on a confidential
basis, pursuant to the PATRIOT Act, and (b) no portion of the Aggregate Subscription Amount to be provided by the undersigned (i)
has been or will be derived from or related to any activity that is deemed criminal under the laws of the United States of America,
or any other jurisdiction, or (ii) is being tendered on behalf of a person or entity that has not been identified to or by the
undersigned; and the undersigned shall promptly notify the Corporation if the undersigned discovers that any of such representations
ceases to be true and provide the Corporation with appropriate information in connection therewith

 

		(l)	the office or other address of the Purchaser at which the Purchaser received and accepted the offer
to purchase the Common Shares is the address listed on this Agreement on the first page of this Agreement;

 

		(m)	it is aware that (i) purchasing, holding and disposing, as applicable, of the Common Shares may
have tax consequences under the laws of both Canada and the United States; (ii) the Corporation gives no opinion and makes no representation
with respect to the tax consequences to the Purchaser under United States, state, local or foreign tax law of the Purchaser's acquisition,
holding or disposition of such Common Shares; (iii) it is solely responsible for determining the tax consequences applicable to
its particular circumstances and should consult its own tax advisors concerning investment in such securities; and (iv) it is aware
that the Corporation may be (in current and future taxable years, and may have been in prior tax years) a "passive foreign
investment company" within the meaning of Section 1297 of the U.S. Internal Revenue Code of 1986, as amended, which could
have adverse consequences for U.S. taxpayers;

 

		(n)	it understands and agrees that the Common Shares have not been and will not be registered under
the U.S. Securities Act, or applicable state securities laws, and the Common Shares are being offered and sold to the Purchaser
in reliance upon exemptions available under Rule 506 of Regulation D under the U.S. Securities Act and/or Section 4(a)(2) of the
U.S. Securities Act;

 

		(o)	it understands and agrees that the financial statements of the Corporation have been prepared in
accordance with Canadian generally accepted accounting principles, which differ in some respects from United States generally accepted
accounting principles, and thus may not be comparable to financial statements of United States companies;

 

		(p)	it has not purchased the Common Shares as a result of any form of "general solicitation"
or "general advertising" (as those terms are used in Regulation D under the U.S. Securities Act), including, but not
limited to, any advertisements, articles, notices or other communications published in any newspaper, magazine or similar media
on the Internet or broadcast over radio, television or Internet or any seminar or meeting whose attendees have been invited by
general solicitation or general advertising;

 

		(q)	it understands and acknowledges that the Corporation is incorporated outside the United States
and its properties are located outside the United States. Consequently, it may be difficult to provide service of process on the
Corporation for court proceedings in the United States and it may be difficult to enforce any judgment against the Corporation
in the United States;

 

		(r)	it understands and acknowledges that no agency, governmental authority, regulatory body, stock
exchange or other entity (including, without limitation, the SEC or any state securities commission) has made any finding or determination
as to the merit of investment in, nor have any such agencies or governmental authorities made any recommendation or endorsement
with respect to, the Common Shares;

 

		(s)	if required by applicable securities legislation, regulatory policy or order or by any securities
commission, stock exchange or other regulatory authority, it will execute, deliver and file and otherwise assist the Corporation
in filing reports, questionnaires, undertakings and other documents with respect to the issue of the Common Shares; and

 

    	 	F-4	 

     

    

		(t)	it acknowledges that the representations, warranties and covenants hereto are made by it with the
intent that they may be relied upon by the Corporation in determining its eligibility or the eligibility of others on whose behalf
it is contracting thereunder to purchase the Common Shares. It agrees that by accepting Common Shares it shall be representing
and warranting that the representations and warranties above are true as at the Closing with the same force and effect as if they
had been made by it at the Closing and that they shall survive the purchase by it of Common Shares and shall continue in full force
and effect notwithstanding any subsequent disposition by it of such securities.

 

The Purchaser undertakes to notify the Corporation immediately
of any change in any representation, warranty or other information relating to the Purchaser or any Beneficial Purchaser set forth
herein which takes place prior to the Closing.

 

Dated: _________________________, 2016.

 

 

	If a Corporation, Partnership or Other Entity:

__________________________________

__________________________________

Name of Entity

__________________________________

__________________________________

Type of Entity

__________________________________

__________________________________

Signature of Person Signing

__________________________________

__________________________________

Print or Type Name and Title of Person Signing	 	If an Individual:

_________________________________

_________________________________

Signature

_________________________________

_________________________________

Print or Type Name

 

 

    	 	F-5	 

     

    

APPENDIX "A"
TO SCHEDULE "F"

 

Declaration for Removal of Legend

 

		TO:	The registrar and transfer agent for the common shares of Zomedica Pharmaceuticals Corp. (the "Corporation").

 

AND TO:                   Zomedica
Pharmaceuticals Corp.

 

The undersigned (A) acknowledges that the sale of the common shares
represented by certificate number _______________, to which this declaration relates, is being made in reliance on Rule 904 of
Regulation S under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), and (B) certifies
that (1) the undersigned is not an "affiliate" (as defined in Rule 405 under the U.S. Securities Act) of the Corporation;
(2) the offer of such securities was not made to a person in the United States and either (a) at the time the buy order was originated,
the buyer was outside the United States, or the seller and any person acting on its behalf reasonably believed that the buyer
was outside the United States, or (b) the transaction was in, executed on or through the facilities of a designated offshore securities
market within the meaning of Rule 902(b) under the U.S. Securities Act, and neither the seller nor any person acting on its behalf
knows that the transaction has been prearranged with a buyer in the United States; (3) neither the seller nor any affiliate of
the seller nor any person acting on any of their behalf has engaged or will engage in any directed selling efforts in the United
States in connection with the offer and sale of such securities; (4) the sale is bona fide and not for the purpose of "washing
off" the resale restrictions imposed because the securities are "restricted securities" (as that term is defined
in Rule 144(a)(3) under the U.S. Securities Act); (5) the seller does not intend to replace such securities with fungible unrestricted
securities; and (6) the contemplated sale is not a transaction, or part of a series of transactions, which, although in technical
compliance with Regulation S, is part of a plan or scheme to evade the registration provisions of the U.S. Securities Act. Unless
otherwise defined herein, the terms used herein have the meanings given to them by Regulation S under the U.S. Securities Act.

 

By: __________________________________ Dated: ____________________________

Signature

Name (please print)

 

 

 

    	 	F-6	 

     

    

SCHEDULE "G"

 

FOR COMPLETION BY ALL SUBSCRIBERS

INFORMATION REGARDING THE SUBSCRIBER

 

Please check the appropriate box (and complete the required information,
if applicable) in each section:

 

		1.	Security Holdings. The Subscriber and all persons acting jointly and in concert with the
Subscriber own, directly or indirectly, or exercises control or direction over (provide additional detail as applicable):

 

		☐	_________________ common shares of Zomedica Pharmaceuticals Corp. (the "Corporation")
and/or the following other kinds of shares and convertible securities (including but not limited to convertible debt, warrants
and options) entitling the Subscriber to acquire additional common shares or other kinds of shares of the Corporation:

 

		☐	No shares of the Corporation or securities convertible into shares of the Corporation.

 

		2.	Insider Status. The Subscriber either:

 

		☐	Is an "Insider" of the Corporation as defined in the Policies of the TSX Venture Exchange
(the "Exchange"), by virtue of being:

 

		(a)	a director or senior officer of the Corporation;

 

		(b)	a director or senior officer of a company that is an Insider or subsidiary of the Corporation;

 

		(c)	a person that beneficially owns or controls, directly or indirectly, voting shares of the Corporation
carrying more than 10% of the voting rights attached to all the Issuer's outstanding voting shares;

 

		(d)	the Corporation itself if it holds any of its own securities.

 

		☐	Is not an Insider of the Corporation.

 

		3.	Pro Group Status. The Subscriber either:

 

		☐	Is a Member of the "Pro Group", which is defined in the Rules of the Exchange as either
individually or as a group:

 

		1.	the member (i.e. a member of the Exchange under the Exchange requirements);

 

		2.	employees of the member;

 

		3.	partners, officers and directors of the member;

 

		4.	affiliates of the member; and

 

		5.	associates of any parties referred to in subparagraphs 1 through 5;

 

		☐	Is not a member of the Pro Group.

 

    	 	G-1	 

     

    

		4.	Corporate Status. If the Subscriber is not an individual (mark one)

 

		(a)	☐  the Subscriber confirms that the Subscriber has filed a Form 4C Corporate Placee
                                                               Registration Form with the Exchange and the information contained in such form is accurate as at the date hereof; or

 

		(b)	☐  the Subscriber has read and duly completed the Form 4C Corporate Placee Registration
                                                               Form, a copy of which follows this form and is marked as Schedule "D", required by the Exchange and authorizes
                                                               the Corporation to file the certification with Exchange.

 

Dated at ____________________________,
this ____ day of __________________________, 2016.

 

	 	 	
        ____________________________________

        (Name of Subscriber – please print)

         

	 	 	
        ____________________________________

        (Telephone Number of Subscriber)

         

	 	 	
        ____________________________________

        (e-mail address)

         

	 	 	
        ____________________________________

        (Signature of Subscriber or Authorized Signatory, as
        applicable)

         

	 	 	
        ____________________________________

        (If applicable, print name of Authorized Signatory and
        Office)

         

 

    	 	G-2	 

     

    

SCHEDULE "H"

 

 

 

 

 

 

FORM 4C

CORPORATE PLACEE REGISTRATION FORM

 

This Form will remain on file with the Exchange and must be completed
if required under section 4(b) of Part II of Form 4B. The corporation, trust, portfolio manager or other entity (the "Placee")
need only file it on one time basis, and it will be referenced for all subsequent Private Placements in which it participates.
If any of the information provided in this Form changes, the Placee must notify the Exchange prior to participating in further
placements with Exchange listed Issuers. If as a result of the Private Placement, the Placee becomes an Insider of the Issuer,
Insiders of the Placee are reminded that they must file a Personal Information Form (2A) or, if applicable, Declarations, with
the Exchange.

 

		1.	Placee Information:

 

		(a)	Name: _______________________________________________________________

 

		(b)	Complete Address: _____________________________________________________

 

		(c)	Jurisdiction of Incorporation
or Creation: _____________________________________

 

	2.	 (a)	Is the Placee purchasing securities
as a portfolio manager: (Yes/No)? ______________

 

		(b)	Is the Placee carrying on business as a portfolio manager outside of Canada:

(Yes/No)? ___________

 

		3.	If the answer to 2(b) above was "Yes", the undersigned certifies that:

 

		(a)	it is purchasing securities of an Issuer on behalf of managed accounts for which it is making the
investment decision to purchase the securities and has full discretion to purchase or sell securities for such accounts without
requiring the client's express consent to a transaction;

 

		(b)	it carries on the business of managing the investment portfolios of clients through discretionary
authority granted by those clients (a "portfolio manager" business) in ____________________ [jurisdiction], and it is
permitted by law to carry on a portfolio manager business in that jurisdiction;

 

		(c)	it was not created solely or primarily for the purpose of purchasing securities of the Issuer;

 

		(d)	the total asset value of the investment portfolios it manages on behalf of clients is not less than
$20,000,000; and

 

		(e)	it has no reasonable grounds to believe, that any of the directors, senior officers and other insiders
of the Issuer, and the persons that carry on investor relations activities for the Issuer has a beneficial interest in any of the
managed accounts for which it is purchasing.

 

    	 	H-1	 

     

    

		4.	If the answer to 2(a). above was "No", please provide the names and addresses of Control
Persons of the Placee:

 

	Name *	City	Province or State	Country
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

*       If the
Control Person is not an individual, provide the name of the individual that makes the investment decisions on behalf of the Control
Person.

 

5.       Acknowledgement - Personal
Information and Securities Laws

 

(a)       "Personal Information"
means any information about an identifiable individual, and includes information contained in sections 1, 2 and 4, as applicable,
of this Form.

 

The undersigned hereby acknowledges and agrees that it
has obtained the express written consent of each individual to:

 

		(i)	the disclosure of Personal Information by the undersigned to the Exchange (as defined in Appendix
6B) pursuant to this Form; and

 

		(ii)	the collection, use and disclosure of Personal Information by the Exchange for the purposes described
in Appendix 6B or as otherwise identified by the Exchange, from time to time.

 

(b)       The undersigned acknowledges
that it is bound by the provisions of applicable Securities Law, including provisions concerning the filing of insider reports
and reports of acquisitions.

 

Dated and certified (if applicable), acknowledged and agreed, at __________________
on _________________________, 2016.

 

___________________________
 (Name of Purchaser – please print)

 

___________________________

(Authorized Signature)

 

___________________________
 (Official Capacity - please print)

 

___________________________

(Please print name of individual whose signature appears
above)

 

THIS IS NOT A PUBLIC DOCUMENT

 

H-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}]]